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INTRODUCTION 
  Bladder cancer is the sixth common cancer in developed 
countries
(1)
 and comprises 3.2% of all cancers. Though the mortality due 
to bladder cancer shows a steady decrease, there is an increase in its 
incidence, especially in females. It is more common in westernised 
countries like North America, United kingdom and Australia. The 
incidence of bladder cancer in India is 3.2% in males and 0.7% in females 
among all malignancies. The two main causes of bladder cancer have 
been smoking and industrial exposure. The industrialised countries show 
a heavy burden of bladder cancer due to increase in smoking, especially 
in females.
(3) 
 Transitional cell carcinoma (TCC) is the commonest carcinoma in 
urinary bladder. However, in countries like Egypt and in parts of African 
continent, squamous cell carcinoma (SCC) predominates.
(2)
 This is due to 
the endemic presence of schistosomiasis which causes chronic irritation 
of the bladder.   
 Though there are many prognostic factors in bladder carcinoma, 
histological stage and grade of the tumour have been considered as 
important factors. In some cases, tumours with higher grade and stage 
behave in an indolent way whereas tumours with lower grade and stage 
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show high incidence of recurrence. Hence additional prognostic 
information is required to guide clinicians in the management of these 
patients. 
 Microvessel density (MVD) has been considered as an important 
prognostic factor in many solid tumours and also in carcinomas of 
bladder.
(4)
. Immunohistological methods can be used to identify the 
density of newly formed blood vessels. The hot-spot method is 
commonly employed where the areas of high MVD are identified in low 
power and then they are counted in high power. Though there are many 
other methodologies in assessing microvessel density, no standard 
technique has yet been adopted either in urology or in general medicine.
(4)
 
Increased MVD has been found to be associated with increased stage, 
grade and increased chances of recurrence.  
 
The HER-2/neu gene is located on chromosome 17 which encodes 
a 185 kilodalton transmembrane protein. The role of HER-2/neu over-
expression has been reported in many tumours like breast, lung, gastric, 
ovarian and oral cancers. HER-2/neu expression in bladder carcinoma has 
been studied by many authors and its expression has been found to range 
from 9% to 81%.
(5)
 This over-expression has been found to be associated 
with increased grade, stage and poorer outcome. Also, targeted therapy is 
being tried in cases of HER-2/neu positive tumours.
(6)
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In this study of 50 cases, an attempt is made to study the role of 
microvessel density and overexpression of HER-2/neu immuno-
histochemically in correlation with stage, grade, recurrence, positive 
urine cytology and other clinico-pathological parameters. 
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AIMS AND OBJECTIVES 
• To identify the incidence and distribution of bladder carcinoma in 
patients admitted in Government General Hospital, Chennai during 
the year 2011-12. 
• To study the histo-morphological features of bladder carcinoma 
including tumour size, tumour location, number, histological type, 
grade, depth of infiltration, stage, squamous metaplasia and 
necrosis.  
• To study the immunological expression of HER-2/neu in bladder 
carcinoma.  
• To study the immunological expression of CD34 in bladder 
carcinoma and to find the microvessel density (MVD) by CD 34 
expression.  
• To evaluate the association of HER-2/neu over expression and 
MVD in relation to clinical stage, histological grade, urine 
cytology positivity and with other prognostic factors.  
• To assess their prognostic significance by following up the patients 
for recurrence.  
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REVIEW OF LITERATURE 
Bladder carcinomas are neoplasms of the bladder arising from the 
lining transitional epithelium. 
 
More than 90% of bladder cancer cases are 
urothelial (transitional cell) carcinomas which originate in the epithelial 
cells that line the bladder wall internally.
(7)
 About 5% of bladder 
carcinomas are squamous cell carcinomas, and less than 2% are 
adenocarcinomas; small cell carcinoma is less common.
(7,9) 
Bladder 
carcinomas can be classified into two types-superficial (80%) and 
invasive disease(20%), on the basis of  their histological appearance. The 
non-muscle-invasive disease has a high recurrence of about 50–70% but 
have a low progression rate of about 15–25% of the patients.(1,3) 
EPIDIMEOLOGY: 
Bladder cancer is the sixth most common malignancy in developed 
countries.
(1,3)  
It ranks as the fourth and ninth most frequently diagnosed 
cancer in men and women, respectively, in the United States.
(1)
 The most 
common type of bladder cancer is transitional cell carcinoma, now 
commonly called the urothelial carcinoma, which is derived from the 
urothelium, constituting more than 90% of bladder cancer cases. 
Squamous cell carcinoma accounts for 1.1% and 2.8% of all bladder 
cancers in men and women respectively. However, its incidence is 
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increased in countries where schistosomiasis is endemic.
(2)
 
Adenocarcinoma of the bladder constitutes 1.5% and 1.9% in men and 
women respectively, of all bladder tumours worldwide.
(15) 
 
ETIOLOGY: 
The etiology of bladder cancer is not yet fully understood; it has 
been classically associated with both exogenous and environmental risk 
factors. The two well known risk factors for bladder carcinoma are 
smoking and occupational exposure.
(3)
 
Smokers have 2-4 times the risk of the general population, with 
heavy smokers being at five times the risk. The exact mechanism by 
which tobacco causes bladder cancer is not yet known, but urothelial 
carcinogens such as acrolein, 4-amino-biphenyl, arylamine, and oxygen 
free radicals have been implicated. The experimental work of McDonald 
and Lund
(10)
 confirmed the carcinogenic properties of β-naphthylamines 
in the production of bladder cancer. Importantly, they also demonstrated 
that the route of exposure to the carcinogen was not the blood stream but 
the urine.
 
Occupational exposure to aniline dyes, aromatic amines such as 2-
naphthylamine and benzidine has been implicated as the second most 
common risk factor for bladder cancer. Benzidine, which is the most 
carcinogenic aromatic amine, has been primarily used in dye production 
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and as a hardener in the rubber industry. Aromatic amines are now 
prohibited, but people exposed to chemical substances from the 
combustion of coal are also known to have an increased risk of bladder 
carcinoma. Occupational bladder cancer has also been observed in gas 
workers, painters, and hairdressers. 
Nutrition also plays a role in bladder cancer. Vitamin A 
supplement showed a reduced risk of bladder cancer, while fried food and 
fat caused an increased risk.
(3)
 A high intake of fluid was shown to reduce 
the risk of bladder cancer in one study but this remains 
controversial.
(3)
Research from Taiwan and Chile has shown an increased 
risk of bladder cancer in populations using drinking water with a high 
content of arsenic. Hence, these and other water contaminants are being 
actively investigated.
(3)
 Consumption of coffee and artificial sweeteners 
were implicated in bladder Carcinoma.
(11,12) 
Other factors implicated in developing bladder cancer and its 
progression include analgesic use, chemotherapeutic agents such as 
cyclophosphamide,
(13,14)
 pelvic radiation, urinary tract infections 
including bacterial, parasitic, fungal, and viral infections and stones in 
bladder. There is a causative relationship between the parasite bilharzias 
and squamous cell carcinoma of the bladder, frequently seen in the 
Middle East patients.
(3) 
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HISTOLOGICAL TYPES: 
 The WHO classification is used for bladder carcinomas (Annexure 
I). Approximately 90% of bladder neoplasms are urothelial carcinomas. 
The remaining 10% comprise all other types of carcinoma, a small 
number of sarcomas, and miscellaneous tumours. The classification of 
urothelial neoplasms is 
Non-invasive urothelial neoplasms
(76)
: 
Urothelial papilloma is a benign neoplasm composed of a delicate 
fibrovascular core covered by normal looking urothelium. The incidence 
is <1% of all bladder tumours.
(78) 
It was first introduced in WHO 
classification 1973 and  is defined as the same in 2004 WHO/ISUP 
classification. 
Inverted urothelial papilloma is a benign neoplasm resembling 
papilloma but having an inverted growth pattern with normal to minimal 
cytologic atypia of the cells.
(79)
 
Papillary urothelial neoplasm of low malignant potential 
(PUNLMP) is a non-invasive papillary urothelial tumour resembling the 
exophytic urothelial papilloma but shows increased layers of epithelium 
compared to the thickness of normal urothelium.
(77)
 The terminology of 
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PUNLMP was first introduced to replace the previously designated WHO 
grade 1 urothelial carcinoma that was defined by the 1998 WHO/ISUP 
classification system. Murphy
(81)
 in 1999, interpreted some of the 1973 
WHO grade 1 tumours as PUNLMP. Later, Cheng et al
(84)
 reported a 
series of 112 patients in 2007 whose bladder tumours showed findings 
consistent with PUNLMP, with up to 35 yr of follow-up (median, >12 
yr), with tumour recurrence in 29% of patients. Bostwick and Mikuz
(82)
 
translated the 1973 WHO grade 1, 2, and 3 tumours as PUNLMP, low 
grade papillary urothelial carcinoma, and high grade papillary urothelial 
carcinoma respectively in the year 2002. Reuter and Melamed
(83)
 
interpreted the 1973 WHO grade 1 tumours as PUNLMP, grade 2 
tumours as low grade papillary urothelial carcinoma, and grade 3 tumours 
as high grade papillary urothelial carcinoma.  
Non-invasive low grade papillary urothelial carcinoma is a 
neoplasm composed of transitional cells lining papillary fronds showing 
an orderly appearance, but the variations in architecture and cytologic 
features are easily recognisable.
(75)
 
Non-invasive high grade papillary urothelial carcinoma is a 
neoplasm composed of urothelium lining the papillary fronds with 
moderate to marked architectural and cytologic atypia. 
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Carcinoma-in-situ is a non-papillary, flat, lesion in which the 
surface epithelium contains cells that are cytologically malignant.
(73,74)
 
Primary carcinoma-in-situ which arises de novo and accounts for 1–3% 
of urothelial neoplasms is most commonly seen in the bladder. The distal 
ureters can be involved in 6–60%, the prostatic urethra in 20–67%, and 
the prostate ducts and acini in up to 40%.
(74) 
Infiltrating urothelial carcinoma: 
These neoplasms are similar to non infiltrating neoplasms except 
for the key feature of invasion which is characterized by nests, clusters, or 
the presence of single cells within the papillary cores, lamina propria or 
into the muscle.  
 This type has numerous variants
(50) 
which include  
Infiltrating urothelial carcinoma with squamous differentiation
(51)
 
which shows the presence of nests of malignant squamous epithelium, 
characterized by polygonal cells that frequently display dyskeratosis, 
keratin pearl formation, and occasional intercellular bridges. Squamous 
differentiation within urothelial carcinoma occurs in about 21% of 
urothelial carcinomas of the bladder and is associated with poorer 
prognosis due to the resistance of squamous elements to chemotherapy 
and radiotherapy.  
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Glandular differentiation
(51)
 Glandular differentiation within 
urothelial carcinoma was first described in the literature in 1968. It occurs 
in 6% of urothelial carcinomas and is defined by the presence of true 
glandular spaces within urothelial carcinoma. These glandular structures 
consist of tubular glands or glands resembling enteric epithelium, often 
associated with variable mucin production.  
 Trophoblastic differentiation
(52)
 was described in 1904. Since 
then, more than 30 cases of tumours with trophoblastic differentiation, 
including cases of pure choriocarcinoma, have been reported. It 
encompasses a wide range of patterns, including formation of 
syncytiotrophoblast, formation of areas resembling pure choriocarcinoma, 
and urothelial carcinomas without giant cells that express human 
chorionic gonadotropin. The presence of trophoblastic differentiation is 
associated with poorer prognosis. 
 Carcinomas with a nested pattern
(53)
 are very rare with an 
incidence of 0.3%. In 1979, Stern made the initial observation of an 
unusual benign-looking bladder carcinoma of “Brunn's nest origin,” and 
since then more than 50 cases have been reported. It is characterized by 
tumour cells with a nested growth pattern, which can be confused with 
von Brunn nests, cystitis cystica, and nephrogenic adenoma. These 
tumours commonly present at high disease stage.
(54)
 Drew et al
(54)
 found 
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that nested variant tumours are associated with progressive or recurrent 
disease. 
 The microcystic variant, has micro and macrocysts and tubular 
structures containing granular eosinophilic material which is PAS and 
Alcian blue positive and necrotic cellular debris. Atleast 25% of the 
tumour should be comprised of microcystic component to designate a 
tumour as microcystic urothelial carcinoma. Microcystic urothelial 
carcinoma was first described in 1991 by Robert H. Young and Lawrence 
R. Zukerberg.
(55) 
Till now, 10 cases
(56,57,58)
 have been reported. The 
presentation and prognosis are similar to conventional invasive urothelial 
carcinoma.
(56,57,58) 
 The micropapillary variant is characterized by a conventional 
infiltrating urothelial carcinoma with an admixed micropapillary pattern 
involving the surface urothelium which consist of slender, delicate 
filiform papillary processes that do not contain distinct fibrovascular 
cores which on cross section, have a glomeruloid appearance. 
Micropapillary variant of urothelial carcinoma was first described by 
Amin and colleagues
(59)
 in the urinary bladder in 1994.  At least 115 
cases
(59,60,561)
 have been described so far. The micropapillary variant of 
urothelial carcinoma is associated with a poorer prognosis, such that even 
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in the absence of muscularis propria in the biopsy, the muscle invasion is 
considered as present. 
 Lymphoepithelioma-like variant is defined as a urothelial 
carcinoma that histologically resembles lymphoepithelioma of the 
nasopharynx. It is characterized by proliferation of primitive anaplastic 
cells infiltrating with a prominent, lymphocytic background. Unlike 
lymphoepithelioma of the nasopharynx, Epstein Barr virus has not been 
found either using immunohistochemistry or in situ hybridization 
technology.
(62)
 Pure and predominant forms of lymphoepithelioma-like 
carcinoma have a more favourable prognosis. When the 
lymphoepithelioma - like morphology is only focally present, the 
expected behavior is the same as for conventional urothelial carcinoma of 
the same grade and stage. 
 The lymphoma-like and plasmacytoid variants of urothelial 
carcinoma exhibit the morphologic features of lymphoma or 
plasmacytoma. This variant of urothelial carcinoma was first described in 
1991 by Zukerberg et al
(63)
 and Sahin et al.
(64)
 Till now, at least 30 cases 
of this variant of urothelial carcinoma have been reported.
(64,65,66)
 Of the 
cases reported, the clinical course following diagnosis has been variable 
with some patients progressing rapidly to death, whereas others have 
presented with better survival. 
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 The giant cell variant of urothelial carcinoma is characterized by 
the presence of tumour giant cells exhibiting marked nuclear atypia, 
along with a component of conventional urothelial carcinoma. These 
tumours have some similarity to the giant cell tumours of the lung. The 
significance of diagnosing the giant cell variant of urothelial carcinoma is 
that it is associated with a poor prognosis.
(67,68) 
 
Sarcomatoid variants are a group of biphasic malignant 
neoplasms exhibiting morphologic evidence of both epithelial and 
mesenchymal differentiation. More than 100 cases have been reported 
since the mid 1800s, many originally classified as carcinosarcoma, but in 
general this is a rare tumour.
(69,70) 
The significance of diagnosing this 
lesion lies in its association with a poor prognosis. These tumours are 
typically diagnosed at advanced local stage, and they often exhibit nodal 
or distant metastases. 70% of patients will die within 2 years of diagnosis. 
 The undifferentiated carcinoma
(71)
 category includes rare 
tumours that cannot be otherwise classified and usually exhibit high-
grade malignant morphology. 
 Clear cell differentiation has been discussed as a distinct variant 
of urothelial carcinoma in 1995 since the presentation of 2 cases was 
done by Kotliar et al.
(72)
 At least 10 cases have been reported, but the true 
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incidence is unclear because of the recent recognition of this type as a 
separate entity. 
 
Figure 1: Gross types of bladder cancers 
HISTOLOGICAL GRADING: 
Histologic grading is one of the most important prognostic factors 
in bladder cancer. Several attempts at grading were done by many 
pathologists. 
The main such systems were those of Ash in 1940, Mostofi’s 
modification of Ash in 1960 (adopted by the American Bladder Tumour 
Registry), Bergkvist et al. in 1965, and Malmstrom et al. in 1987. The 
first widely accepted grading system for papillary urothelial neoplasms 
was the WHO (1973) classification system, which divided urothelial 
tumours into four categories: papilloma, grade 1 carcinoma, grade 2, and 
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grade 3.
(16)
 Histologic grading is based on the degree of cellular anaplasia, 
with grade 1 tumours having the least degree of anaplasia, but compatible 
with a diagnosis of malignancy; grade 3 tumours have the most severe 
degree of anaplasia, and grade 2 have an intermediate degree of cellular 
anaplasia. Anaplasia is further defined by the authors of the WHO (1973) 
classification as increased cellularity, nuclear crowding, alteration in 
polarity of cells, failure of differentiation from the base to the surface, 
nuclear pleomorphism, variations in nuclear chromatin pattern, displaced, 
abnormal mitotic figures, and giant cells. The WHO grading system 
divides bladder cancer into 4 types based on grade such as papilloma, 
grade1TCC, grade 2 TCC and grade 3 TCC.  
PAPILLOMA: 
 This is a benign neoplasm having papillae lined by normal 
appearing transitional epithelium. 
GRADE 1 UROTHELIAL CARCINOMA: 
Grade 1 papillary carcinoma consists of an orderly arrangement of 
transitional cells lining delicate papillae with minimal architectural 
abnormality and minimal nuclear atypia. The urothelium is often 
thickened to more than seven cell layers but there is minimal complexity 
and fusion of the papillae. The urothelium displays normal maturation 
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and cohesiveness, with intact superficial layer of cells. They have fine 
granular chromatin and mitotic figures are usually rare. They are 
commonly seen around the ureter (69%). Since recurrence can still occur 
in these patients, long term follow-up is recommended for these cases. 
GRADE 2 UROTHELIAL CARCINOMA: 
Grade 2 carcinomas retain some of the orderly architectural 
appearance and maturation of grade 1 carcinoma, but they display focal 
moderate variation in orderliness. Cytologic abnormalities are present, 
with moderate degree of nuclear crowding, moderate loss of cell polarity, 
moderate degree of nuclear hyperchromasia, moderate anisonucleosis, 
and occasional prominent nucleoli. Mitotic figures can be seen but are 
usually limited to the lower half of the urothelium. Superficial cells 
(umbrella cells) are usually present.  
Some authors consider both nuclear pleomorphism and mitotic 
count as criteria for subdividing grade 2 urothelial cancer (grade 2A and 
2B), and they have been successful in identifying groups of patients with 
urothelial cancers with different outcomes.
(17,18) 
However, sub 
classification of grade 2 urothelial carcinoma is not recommended by 
some authors because of significant inter observer variability. The risk for 
17
 
 
 
 
recurrence in patients of grade 2 urothelial carinoma is 45–67% and 
progression to invasion can occur in about 20% of patients. 
GRADE 3 UROTHELIAL CARCINOMA: 
There is obvious loss of normal architecture and cell polarity, and 
frequent atypical mitotic figures. The superficial cell layer is partially or 
completely absent, accompanied by prominent cellular dyscohesion. 
Cellular anaplasia characterised by hyperchromasia, nuclear crowding, 
failure of differentiation and giant cells is frankly evident. Mitosis can be 
seen in all levels of epithelium and multiple nucleoli may be evident.  The 
papillae may appear fused and branching. The recurrence risk for patients 
with non-invasive grade 3 cancer is 65–85%, with in cases of invasive 
cancer recurrence occurs in 20–52% of patients. 
In 1998, a revised system for grading non-invasive papillary 
urothelial neoplasms of the urinary bladder was proposed and was 
subsequently formally adopted by the World Health Organization. 
  In 2004, a grading system for non-invasive papillary urothelial 
neoplasms was given by International Society of Urologic Pathology 
(ISUP), which was later accepted by WHO. According to this new 
system, noninvasive papillary urothelial neoplasms are divided into four 
categories namely papilloma, papillary urothelial neoplasm of low 
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malignant potential (PUNLMP), low-grade papillary urothelial 
carcinoma, and high-grade papillary urothelial carcinoma. 
INTERNATIONAL SOCIETY OF UROLOGICAL PATHOLOGY/ 
WHO(2004) CLASSIFICATION: 
PAPILLOMA: 
 This entity is similar to the one described in 1973 WHO 
classification consisting of papillae lined by benign looking transitional 
epithelium. 
PAPILLARY UROTHELIAL NEOPLASM OF LOW MALIGNANT 
POTENTIAL (PUNLMP): 
PUNLMP is a low-grade urothelial tumour with a papillary 
architecture. This lesion is histologically defined by the WHO (2004) 
classification system as a papillary urothelial tumour resembling the 
exophytic urothelial papilloma, but with increased cellular proliferation 
exceeding the thickness of normal urothelium and minimal atypia; 
polarity is generally preserved in these tumours. All such tumours would 
have been considered grade 1 urothelial carcinomas by the WHO 1973 
grading system.  
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LOW GRADE UROTHELIAL CARCINOMA: 
A low-grade papillary urothelial carcinoma shows slender papillae 
with frequent branching and variation in nuclear polarity, nuclei show 
enlargement and irregularity; chromatin is vesicular, and nucleoli are 
often present. Mitotic figures may occur at any level. The majority of 
these cases would have been considered as grade 2 in the WHO (1973) 
classification. Most patients have a single tumour in the posterior or 
lateral bladder wall. However, 22% of patients with low-grade papillary 
urothelial carcinoma have two or more tumours. Tumour recurrence, 
stage progression and tumour-related mortality are 50%, 10% and 5%, 
respectively. 
HIGH GRADE UROTHELIAL CARCINOMA: 
The cells lining the papillary fronds show an obviously disordered 
arrangement with cytologic atypia. All tumours classified as grade 3 in 
the 1973 WHO scheme, as well as some assigned grade 2 in that 
classification, would be considered high grade carcinoma in the 2004 
WHO classification. The papillae are frequently fused. The nuclei are 
pleomorphic with prominent nucleoli. Polarity is altered. Mitotic figures 
are frequent. Carcinoma in situ is frequently evident in the adjacent 
mucosa. These tumours can occur as single or multiple lesions. Stage 
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progression and death due to disease can be seen in as many as 65% of 
patients. 
Other recent proposals for bladder cancer grading: 
The Ancona 2001 refinement of the 1973 WHO classification
(19)
 
divides urothelial tumours into two main groups based on growth pattern: 
flat and papillary. Flat tumours include reactive changes, dysplasia, and 
carcinoma in situ. Papillary tumours include papilloma, grade 1 papillary 
carcinoma, grade 2 papillary carcinoma, and grade 3 papillary carcinoma. 
The publication of the 1999 WHO blue book introduced a new 
grading scheme.
(20)
 This new classification retained the three-tiered 
numbering system (grade 1, grade 2, and grade 3 carcinoma), but tumours 
formerly classified as 1973 WHO grade 1 were subdivided into PUNLMP 
and grade 1 tumours. Papillary tumours were subclassified as papilloma, 
papillary urothelial neoplasm of low malignant potential, grade 1, grade 
2, and grade 3 papillary urothelial carcinoma 
STAGING: 
 The TNM staging system (Annexure II) is widely used in western 
countries. It is the best available predictor of prognosis and is 
recommended in India also. 
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Early/Superficial bladder cancer is otherwise called as non-muscle 
invasive cancer carcinoma in situ, Ta tumours and T1 tumours are 
included under superficial bladder carcinoma.  
Invasive bladder cancer includes T2 and T3 tumours. In T2 lesion 
the tumour has spread to the muscle layer whereas in case of T3 tumours, 
it has it has grown through the muscle layer.  
Advanced bladder cancer is the one which is widespread outside 
the bladder. It includes T4 bladder tumours. 
 
Figure 2: Staging of bladder cancers 
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PROGNOSTIC FACTORS IN BLADDER CARCINOMA: 
Prognostic factor is defined as any variable that provides 
information useful in assessing the outcome at the time of diagnosis of 
the disease. The prognostic factors are classified as clinical factors, 
pathological factors and genetic/molecular factors. 
 The clinical factors
(80)
 include patient age and a previous history of 
bladder cancer.  
 AGE: Younger patients with bladder cancer appear to have a 
favourable prognosis, because they usually present as superficial tumours 
and low-grade tumours. 
RECURRENCE: Mullerad et al and Kang et al reported that a 
previous history of bladder cancer was an independent predictor of 
cancer-specific survival. 
The pathological factors play more useful role in assessing prognosis. It 
includes the following 
1. SIZE: Tumour size > 5 cm has been associated with 35% of 
invasion compared to 9% invasion in small bladder tumours and is 
associated with poorer prognosis.
(21) 
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2. LOCATION: Tumours arising from the bladder neck are 
associated with a poorer prognosis. Tumours of the bladder dome tend to 
present as higher-grade lesions, whereas tumours of the lateral walls and 
the ureteric orifices tend to be of lower grade.
(26) 
3. NUMBER: Multiple tumours present more frequently with 
recurrence (40-90%) when compared to single tumours (18-60%).
 (22) 
3. HISTOLOGICAL TYPE: Non-papillary TCCs tend to present as 
higher grade, stage and more aggressive tumours.
(107) 
4. LYMPH NODE INVOLVEMENT: Lymph node involvement is 
associated with increased chances of recurrence and disease progression 
and has an overall poor outcome.
(108) 
5. STAGE: Since Ta lesions are confined to basement membrane 
they are associated with good prognosis. As the tumour invades the 
muscle layer the prognosis become poorer.
(23) 
6. GRADE: Grade is an important prognostic indicator for 
progression, mortality and recurrence.
(24)
 High grade tumours are 
associated with increased chances of recurrence and have a high risk of 
progression to muscle invasive disease. 
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7. CARCINOMA-IN-SITU CHANGES: Recurrence rates are 
higher in transitional cell carcinomas which have associated carcinoma-
in-situ changes involving the adjacent mucosa.
(25) 
8. LYMPHO-VASCULAR INVASION: This feature, as 
determined microscopically with H&E stain or by vascular stains in either 
lymph vessels or blood vessels, is associated with an increased rate of 
recurrence.
(27) 
9. SQUAMOUS METAPLASIA: Squamous metaplasia in 
transitional cell carcinomas are fairly common and this squamous 
epithelium resist radiotherapy. Hence they have a poor prognosis when 
they present in inoperable stage.
(90) 
The molecular factors which are associated with prognosis are 
1. MICROVESSEL DENSITY: This feature is alleged to be an 
independent prognostic indicator which is associated with increased 
stage, and more chances of recurrence.
(28) 
2. P53 OVEREXPRESSION: Nuclear over expression of P53 is 
related to both grade and stage of bladder carcinoma.
(29)
. 
3. ALTERED EXPRESSION OF RB GENE: Tumours exhibiting 
reduced expression of the RB protein have an aggressive behaviour than 
those without reduced expression.
(30) 
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4. LOSS OF E-CADHERIN: Tumours showing loss of E-cadherin 
has worse prognosis than those in which this surface antigen was 
present.
(31) 
5. HER 2/NEU EXPRESSION: Increased HER-2/neu expression 
of this marker is associated with higher grade, stage and metastatic 
growth.
(32) 
IMMUNOHISTOCHEMISTRY (IHC): 
Albert Coons et al in 1941 first labelled antibodies directly with 
fluorescent isocyanate. Nakane and Pierce et al in 1966, introduced the 
indirect labelling technique in which the unlabelled antibody is followed 
by second antibody or substrate. Various stages of development of 
immunohistochemistry include peroxidase – antiperoxidase method 
(1970), alkaline phosphatase labelling (1971), avidin biotin method 
(1977) and two layer dextrin polymer technique (1993).
(33) 
Antigen retrieval: 
 
Antigen retrieval can be done by the following different techniques to 
unmask the antigenic determinants of fixed tissue sections.
 
1. Proteolytic enzyme digestion 
2. Microwave antigen retrieval 
26
 
 
 
 
3. Pressure cooker antigen retrieval 
4. Microwave and trypsin antigen retrieval 
PROTEOLYTIC ENZYME DIGESTION: 
Huank et al in 1976 introduced this technique to breakdown 
formalin cross linkages and to unmask the antigen determinants. The 
most commonly used enzymes include trypsin and proteinase. The 
disadvantages include over digestion, under digestion and antigen 
destruction. 
MICROWAVE ANTIGEN RETRIEVAL: 
This is a new technique most commonly used in current practice. 
Microwave oven heating involves boiling formalin fixed paraffin sections 
in various buffers for rapid and uniform heating.  
PRESSURE COOKER ANTIGEN RETRIEVAL:  
Miller et al in 1995 compared and proved that pressure cooking 
method has fewer inconsistencies, less time consuming and can be used 
to retrieve large number of slides than in microwave method. 
PITFALLS OF HEAT PRETREATMENT: 
Drying of sections at any stage after heat pretreatment destroys 
antigenicity. Nuclear details are damaged in poorly fixed tissues. Fibers 
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and fatty tissues tend to detach from slides while heating. Not all antigens 
are retrieved by heat pretreatment and also some antigens like PGP 9.5 
show altered staining pattern. 
DETECTION SYSTEMS: 
After addition of specific antibodies to the antigens, next step is to 
visualize the antigen antibody reaction complex. The methods employed 
are direct and indirect methods.  
In the direct method, primary antibody is directly conjugated with 
the label. Most commonly used labels are flouro-chrome, horse radish 
peroxidase and alkaline phosphatase. Indirect method is a two-step 
method in which labeled secondary antibody reacts with primary 
antibody bound to specific antigen. The use of peroxidase enzyme 
complex or avidin biotin complex further increases the sensitivity of 
immunohistochemical stains
(33)
.
 
In 1993, Pluzek et al introduced enhanced polymer one step 
staining, in which large numbers of primary antibody and peroxidase 
enzymes are attached to dextran polymer back bone. This is a rapid and 
sensitive method
(37)
. 
28
 
 
 
 
Dextran polymer conjugate two step visualization system is based 
on dextran technology in Epos system. This method has greater 
sensitivity and is less time consuming. 
Uses of IHC in bladder pathology
 (34)
 
1. Assessment of prognosis by using markers for microvessel density 
(CD 34, CD 31, VEGF), HER-2/neu, P53, EGFR and other markers. 
2. Assessment of metastatic lesions of possible bladder origin by 
using antibodies to CK7 and CK20, uroplakin, thrombomodulin as well 
as 34βE12 and 4A4. 
3. Evaluation of spindle cell lesions to distinguish sarcomatoid 
carcinoma from mesenchymal lesions. 
MICROVESSEL DENSITY: 
Tumour stage and histopathological grade are the most important 
prognostic factors affecting the survival of bladder carcinoma, but 
tumours with similar stage and grade may show different outcome. Thus 
there is some evidence that some other prognostic factors also play a role 
in prognosis of patients. A majority of studies have assessed the 
prognostic value of measuring tumour angiogenesis (i.e., measurement of 
tumour microvessel densities) and have found a positive association 
between increasing microvessel densities and prognosis.
(28) 
Angiogenesis 
or neovascularization is by definition formation of new capillaries from 
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pre-existing blood vessels. The process of neovascularization in tumours 
is regulated by the combined action of tumour cells, stromal cells and 
inflammatory cells.
(38)
 Neovascularisation is essential for both benign and 
malignant tumours especially when it grows beyond 2 mm
3
. Microvessel 
density has been shown to add to prognostic information in a number of 
solid tumours including prostate (Weidner et al, 1993), colon (Takahashi 
et al, 1995), lung (Mattern et al, 1996) and breast cancer (Linderholm et 
al, 1999). Microvessel density, has also recently been proven to add 
prognostic information in bladder carcinoma. However, contradictory 
results have also been reported;
(39)
 this may be due to significant 
differences in the methods employed for sample selection, techniques of 
immunostaining, counting of vessels and statistical analysis, although a 
number of biological differences may account for the discrepancy. 
MICROVESSEL DENSITY BY IMMUNOHISTOCHEMISTRY: 
 Immunohistochemically, the blood vessels are identified by 
highlighting them using specific markers. Targeted therapy has been 
useful in cases of marker positive tumours. The markers can be divided 
into panendothelial markers and markers which bind selectively with the 
activated endothelium. The examples of panendothelial markers are CD 
31 and CD34 which bind with all small and large vessels. The problems 
in these markers are staining of other cells- like staining of lymphatics by 
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CD 31 and staining of inflammatory cells by CD 34. These can be 
reduced to some extent by pre treatment with microwave oven. The 
activated endothelial markers like CD 105 bind specifically to the 
proliferating endothelium and hence do not stain for normal blood vessels 
or lymphatics. Thus they are more specific as a marker of angiogenesis. 
 Vascular hot spots are defined as regions of high vascular density 
within the tumour. This was first described by Weidner et al, 1991in 
breast cancer.
(85)
 These hot spots can be identified by inspecting the 
sections under low power. Atleast 10 of these hot spots should be 
analysed so that the chance of missing them is reduced. They are seen 
predominantly at the peripheral margins of the tumour. Once the vascular 
hot spot is identified, they are viewed under high power to count 
individual microvessels. The counting can be done either manually or by 
using Computerised Image Analysis systems. Magnifications of the order 
of 200 – 400X and field sizes ranging from 0.12 to 1.00 mm2 have been 
used by Vermeulen et al, (1996). A higher magnification improves the 
detail of the image and allows the identification of even single endothelial 
cell. According to Weidner et al (1991), any highlighted endothelial cell 
or cell cluster clearly separate from adjacent microvessels, tumour cells 
and other connective tissue elements should be regarded as a distinct 
countable microvessel. A lumen or the presence of red blood cells is not 
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necessary to identify a microvessel. However the cut-off calibre size 
necessary to designate a microvessel has not been specified by many 
authors and hence even single endothelial sprout and a large calibre 
vessel are included in counting. Atleast three different areas of vascular 
hot spots are counted in 200X magnification and the highest of these is 
taken as the microvessel density. 
 The mean microvessel density can be calculated after the tumour is 
divided into characteristic groups. The values are compared and statistical 
significance is calculated. 
 Computerised Image Analysis Systems is an automated counting 
technique that improves reproducibility and reduces inter-observer 
variability. According to Wakui et al (1992) and Visscher et al (1993), it 
has been considered as a more objective method of assessing microvessel 
density. Additional parameters like the number of vessels with a certain 
dimension range, the vessel luminal area, vessel luminal perimeter and 
the number of immunostained areas per microscopic field can also be 
assessed.
(28) 
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HER-2/NEU RECEPTORS: 
The HER-2/neu gene was originally called ‘neu’ as it was first 
derived from rat neuro/glioblastoma cell lines. Coussens and coworkers 
named it HER2 because its primary sequence was very similar to Human 
Epidermal Growth Factor receptor (EGFR or ERBB or ERBB1).
(86)
 This 
human proto-oncogene, also known as c-erbB2, ErbB-2 is a 185-
kilodalton transmembrane receptor tyrosine kinase located at 
chromosome 17q. These proteins belong to subclass I of the super-family 
of receptor tyrosine kinases. They are expressed in many tissues of 
epithelial, mesenchymal, and neuronal origin and are critical for cell 
proliferation and tissue differentiation. The clinical significance of HER-
2/neu has already been evaluated in colorectal, breast, stomach, lung, 
head and neck, pancreatic, urothelial carcinoma, and gliomas and prostate 
cancers; patients with elevated HER-2/neu demonstrate poor survival 
compared with patients with lower level of HER-2/neu.
(46,47,48)
  
Several studies have reported an association between prognosis and 
HER-2/neu gene over expression in bladder cancers. HER 2/neu protein 
over expression and HER-2/neu gene amplification were correlated with 
higher histologic tumour grade and invasion in many studies. The first 
report of increased amplification and over expression of the HER-2/neu 
in bladder carcinoma was reported by Zhau HE, Zhang X, von 
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Eschenbach AC, et al in 1990.
(40)
 Till then there were many studies which 
showed an association of HER-2/neu expression with increased grade and 
stage in bladder carcinomas.
(41,42,43)
Some studies also showed that HER-
2/neu was an independent variable in determining patient survival.
(44,45)
T 
he prevalence of HER-2/neu expression in bladder carcinomas has ranged 
from 2% to 81% . In a recent study by Lae M, Couturier J, Oudard S, 
Radvanyi F et al in 2010, HER-2/neu protein over-expression was found 
in 9.2%, while HER-2/neu gene amplification was found in 5.1% of 
tumour specimens.
(49)
 HER-2/neu can be assayed by immuno 
histochemistry for protein over expression and by fluorescent in situ 
hybridization for gene amplification.  
The scoring system which is used for HER-2/neu expression in 
bladder cancers is  
Staining pattern Score 
Her2neu 
expression 
No staining 0 Negative 
Weak staining in part of membrane of 
less than 10% of the cells. 
1 Negative 
Complete membranous staining of weak 
or moderate intensity in >10% of tumour 
cells. 
2+ Positive 
Strong complete membranous staining in 
more than 10 % of tumour cells creating 
a fish net pattern. 
3+ Positive 
 
Positive staining is considered when the score is 2+ or 3+ and the absence 
of cytoplasmic staining. 
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MATERIALS AND METHODS 
This study is a combined retrospective and prospective descriptive 
study of bladder carcinomas conducted in the Institute of Pathology, 
Madras Medical College and Rajiv Gandhi Government General 
Hospital, Chennai during the period between January 2010 and December 
2011.  
A total of 19,898 cases were submitted to the Department of 
Pathology, Rajiv Gandhi Government General hospital during the period 
of January 2010 to December 2011 for histopathological examination. 
Out of that, 143 cases were bladder cases. Among them, 13 specimens 
were radical cystectomies, 2 specimens were simple cystectomies, 90 
specimens were TURBT and 38 specimens were small biopsies. The total 
number of non- neoplastic and malignant cases of the urinary bladder was 
27 and 116 respectively.  
Out of the malignant cases, 114 cases were carcinomas, one was a 
case of inflammatory myofibroblastic tumour and another one was a case 
of leiomyosarcoma of bladder. Out of the 114 cases, 101 were TCCs, 7 
cases were adenocarcinomas and 6 cases were SCCs. The TCC cases 
numbering 101 were taken up for the study. 
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Source of data: 
The bladder carcinoma cases reported in the Institute of Pathology, 
Madras Medical College and Rajiv Gandhi Government General hospital 
from January 2010 to December 2011 which have been sent by the 
Department of Urology. 
Inclusion criteria: 
 All the cases of transitional cell carcinomas reported in bladder 
specimens irrespective of the age and sex and the procedure done were 
included for the study. 
Exclusion criteria: 
 Non-neoplastic lesions and benign neoplasms of the bladder. 
 Carcinomas other than transitional cell carcinomas. 
 Cases with inadequate material. 
Method of data collection: 
 Detailed history of the cases regarding age, sex, history, type of 
procedure, site, size, stage, previous surgery details and urinary cytology 
were obtained for all the 101 transitional cell carcinomas reported during 
the period of study from surgical pathology records. Hematoxylin and 
Eosin stained 4 µ thick sections of the paraffin tissue blocks of specimens 
were reviewed. The following clinical and pathological parameters were 
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evaluated: Age, gender, tumour size and tumour location (base, lateral, 
posterior walls and trigone). 
  Carcinomas were classified as transitional cell type which includes 
papillary/non-papillary, invasive/non-invasive and any other special types 
like lymphoepithelial carcinoma, sarcomatoid carcinoma. Other 
parameters like squamous metaplasia, necrosis and sarcomatoid 
component were noted. Regarding the depth of invasion, the carcinomas 
were classified into 4 groups: T1 (invasion of mucosa and submucosa), 
T2 (invasion of muscle layer in which T2a is invasion of superficial 
muscle and T2b is invasion of deep muscle), T3 (invasion of perivesical 
tissue in which T3a means microscopic involvement and T3b means 
macroscopic involvement) and T4 (invasion of adjacent organs in which 
T4a is invasion of prostate, uterus and vagina and T4b is involvement of 
pelvic and abdominal wall), and according to grade the carcinomas were 
divided into 3 groups: PUNLUMP, low grade urothelial carcinoma and 
high grade urothelial carcinoma according to the recommendations of the 
WHO (2004). Carcinoma staging was done according to TNM 
classification of bladder carcinomas (Annexure-II). The tumours were 
further evaluated for the presence of infiltration, necrosis, squamous 
metaplasia and were graded as present or absent. 50 cases of bladder 
carcinomas of varying grades were randomly selected from the total cases 
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and their representative formalin fixed paraffin embedded tissue samples 
were subjected to immunohistochemistry for a panel of 2 markers- CD 34 
and HER-2/neu. 
Immunohistochemical evaluation: 
Immuohistochemical analysis of markers CD 34 and HER-2/neu 
were done in paraffin embedded tissue samples using Super-sensitive 
polymer HRP system based on non-biotin polymeric technology. 4 µ 
thick sections from formalin fixed paraffin embedded tissue samples were 
transferred on to gelatin coated slides. Heat induced antigen retrieval was 
done. The antigen was bound with mouse monoclonal antibody 
(Biogenex) against CD 34 protein and HER-2/neu protein and then 
detected by the addition of secondary antibody conjugated with horse 
radish peroxidase-polymer and diaminobenzidine substrate. The step by 
step procedure of Immunohistochemistry is given in Annexure III. 
Antigen Vendor Species(clone) Dilution 
Positive 
control 
CD 34 Biogenex Mouse 
Ready to 
use 
Bladder 
HER-2/neu Biogenex Mouse 
Ready to 
use 
Bladder 
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Interpretation and scoring system: 
The immunohistochemically stained slides were analyzed for the 
presence of reaction, cellular localization, percentage of cells stained and 
intensity of reaction. Membrane staining was assessed for HER-2/neu and 
cytoplasmic staining for CD 34. 
  HER-2/neu immuno-reactivity was assessed as being positive when 
tumours exhibited intense nuclear staining and absent cytoplasmic 
staining and was categorized into 2 groups: 2+ (complete membranous 
staining of weak or moderate intensity in >10% of tumour cells) and  
3+(strong complete membranous staining in more than 10 % of tumour 
cells creating a fish net pattern) 
CD 34 staining in the endothelial cells was noted. Any highlighted 
endothelial cell or cell cluster clearly separate from adjacent 
microvessels, tumour cells and other connective tissue elements were 
regarded as a distinct countable microvessel. A lumen or the presence of 
red blood cells was not taken as an essential criteria to identify a 
microvessel. Hot spots were identified and atleast 3 such hot spots were 
identified under 200X power and the vessels were counted. The 
maximum of these was taken as microvessel density. The mean 
microvessel density was calculated in relation to the prognostic factors.  
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Statistical analysis : 
The statistical analysis was performed using statistical package for 
social science software version 11.5 which consisted computing the 
frequency counts and percentages for qualitative variables and mean for 
the quantitative variables.  The expression of microvessel density was 
correlated with clinico- pathological factors like gender, tumour site, 
tumour configuration, size, histological types, histological grade, depth of 
infiltration, stage, squamous metaplasia, necrosis, sarcomatoid 
component, urine cytology and recurrence using the Student t-test and  
Anova t-test. HER-2/neu was also correlated with these parameters using 
Pearson’s Chi –Square test. 
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OBSERVATION AND RESULTS 
 In the study period of 24 months from January 2010 to December 
2011, a total of 19,898 specimens were received in the Institute of 
Pathology, Madras Medical College for histological examination. Total 
numbers of bladder specimens received were 143. The total number of 
non-neoplastic and malignant cases was 27 and 116 respectively. Out of 
116 malignant cases 114 cases were carcinomas, 1 was a case of 
Inflammatory myofibroblastic tumour of bladder and another 1 was a 
case of leiomyosarcoma. Thus the distribution of non-neoplastic lesions 
was 20.9%, and of malignant tumours were 81.1% among the bladder 
specimens. 
Among the 143 bladder specimens, there were 13 radical 
cystectomies, 2 simple cystectomies, 90 TURBTs and 38 small biopsies. 
All 13 radical cystectomies were done to treat bladder carcinoma. Out of 
2 simple cystectomies 1 was done for carcinoma and 1 for inflammatory 
myofibroblastic tumour.  
Of the 114 total carcinomas arising from the bladder, transitional 
cell carcinomas were the most common constituting 101 cases accounting 
for 88.6% of carcinomas. Adenocarcinoma of bladder constituted 7 cases 
accounting for 6.1% and squamous cell carcinoma constituted 6 cases 
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accounting for 5.3% of carcinomas arising from urinary bladder (Table 1 
and chart 1) 
TABLE : 1 - HISTOLOGICAL SUBTYPES OF BLADDER 
CARCINOMAS 
Histological subtypes Number of cases(N) Percentage 
Transistional cell carcinoma 101 88.6% 
Adenocarcinoma 7 6.1% 
Squamous cell carcinoma 6 5.3% 
Total number of cases 114 100% 
 
Transitional cell carcinomas had a peak incidence in the age group 
of 61-70 years. The youngest age of presentation of bladder cancer was at 
22 years in this study. The mean age was 58.74. (Table 2 and chart 2) 
TABLE : 2 - AGE WISE DISTRIBUTION OF TRANSITIONAL 
CELL CARCINOMAS 
Age group Number of cases Percentage 
21 - 30 years 1 1% 
31 - 40 years 7 7% 
41 - 50 years 17 16.8% 
51 - 60 years 29 28.7% 
61 - 70 years 32 31.7% 
71 - 80 years 13 12.9% 
81 - 90 years 2 1.9% 
Total cases 101 100% 
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Among the 101 cases of transitional cell carcinomas, 79 (78.2%) 
cases were reported in males and 22 (21.8%) cases were reported in 
females. (Table 3 & Chart 3) 
TABLE : 3 - SEX DISTRIBUTION IN TRANSITIONAL CELL 
CARCINOMAS 
Sex Total number of cases Percentage 
Male 79 78.2% 
Female 22 21.8% 
Total 101 100% 
 
In this study, 38(37.7%) cases involved the right lateral wall, 
30(29.8%) cases involved the left lateral wall, 4(3.9%) involved the 
posterior wall, 6(5.9%) involved the base, 7(6.9%) involved the dome, 
10(9.9%) involved the entire bladder and in 6(5.9%) cases the tumour 
was multiple. (Table 4 and Chart 4) 
TABLE : 4 - DISTRIBUTION OF SITE OF INVOLVEMENT IN 
TRANSITIONAL CELL CARCINOMAS 
Site of bladder cancer Number of cases Percentage 
Right lateral wall 38 37.7% 
Left lateral wall 30 29.8% 
Posterior wall 4 3.9% 
Base  6 5.9% 
Dome 7 6.9% 
Entire bladder 10 9.9% 
Multiple 6 5.9% 
Total  101 100% 
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Among the 101 cases, 95 tumours (94%) were single and 6 
tumours were multiple (6%) (Table 5 and chart 5). 
 
TABLE : 5 - TUMOUR NUMBER IN TRANSITIONAL CELL 
CARCINOMAS 
Tumour number Number of cases Percentage 
Single  95 94% 
Multiple  6 6% 
Total  101 100% 
  
The mean size of the tumours which ranged from 0.5 to 10 cm was 
4.1 cm. 65(64.4%) were < 4cm and 36(35.6%) were > 4cm (Table 6 and 
chart 6). 
 
TABLE : 6 - DISTRIBUTION OF SIZE IN TRANSITIONAL CELL 
CARCINOMAS 
Size Number of cases Percentage 
<4cm 65 64.4% 
>4cm 36 35.6% 
Total 101 100% 
 
Among the 101 transitional cell carcinomas, 83 cases were 
papillary and 18 cases were non-papillary. (Table 7 and chart 7) 
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TABLE : 7 - HISTOLOGICAL APPEARANCE OF 
TRANSITIONAL CELL CARCIINOMAS 
Appearance Number of cases Percentage 
Papillary 83 82.2% 
Non-papillary 18 17.8% 
Total 101 100% 
 
Among the 101 transitional cell carcinomas, 74 cases were low 
grade and 27 cases were high grade. (Table 8 and chart 8). 
 
TABLE : 8 - DISTRIBUTION OF HISTOLOGICAL GRADE IN 
TRANSITIONAL CELL CARCINOMAS 
Grade Number of cases Percentage 
Low grade 74 73.3% 
High Grade 27 26.7% 
Total 101 100% 
 
In this study, 71 cases were infiltrative and 30 cases were non-
infiltrative (Table 9). 
TABLE : 9 - INFILTRATION IN TRANSITIONAL CELL 
CARCINOMAS 
Infiltration Number of cases Percentage 
Infiltrative 71 70.3% 
Non-infiltrative 30 29.7% 
Total  101 100% 
45
 
 
 
 
Out of the 71 infiltrative cases, 41 cases(57.8%) showed infiltration 
upto subepithelial connective tissue, 23 cases(32.4%) showed infiltration 
upto superficial muscle layer, 3 cases(4.2%) showed infiltration upto 
deep muscle layer, 1 case(1.4%) showed microscopic involvement of 
perivesical tissue and 3 cases(4.2%) showed involvement of prostrate. 
There were no cases with lymphnode involvement. (Table 10). 
TABLE : 10 - DISTRIBUTION OF TRANSITIONAL CELL 
CARCINOMAS ACCORDING TO DEPTH OF INVASION 
Depth of invasion Number of cases Percentage 
Ta 30 29.7% 
T1 41 40.6% 
T2a 23 22.7% 
T2b 3 3% 
T3b 1 1% 
T4a 3 3% 
Total 101 100% 
 
In the present study, 41 cases (57.7%) belonged to stage I, 26 cases 
(36.6%) belonged to stage II and 4 cases (5.7%) belonged to stage III. 
(Table 11 and Chart 9) 
46
 
 
 
 
TABLE : 11 - DISTRIBUTION OF TRANSITIONAL CELL 
CARCINOMAS ACCORDING TO STAGE 
STAGE 
NUMBER OF 
CASES 
PERCENTAGE 
0 30 29.7% 
I 41 40.6% 
II 26 25.7% 
III 4 4% 
Total 101 100% 
 
In this study, squamous differentiation was seen in 15 cases, 
necrosis was seen in 19 cases and sarcomatous component was seen in 3 
cases. (Table 12 and chart 10) 
TABLE : 12 - DISTRIBUTION OF OTHER PROGNOSTIC 
FACTORS IN TRANSITIONAL CELL CARCINOMA 
Patient characteristics Present Absent Total 
Squamous metaplasia 15(14.9%) 86(85.1%) 101(100%) 
Necrosis 19(18.8%) 82(81.2%) 101(100%) 
Sarcomatous component 3(3%) 97(97%) 101(100%) 
   
Among the 101 cases, urine cytology was done in 24 cases, out of 
which 14 cases were positive for malignant cells and 10 cases were 
negative for malignant cells. (Table 13 and chart 11) 
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TABLE : 13 - URINE CYTOLOGY IN TRANSITIONAL CELL 
CARCINOMAS 
Urine cytology Number of cases Percentage 
Positive 14 58.3% 
Negative 10 41.7% 
Total 24 100% 
 
In our study, 30 cases were associated with recurrence. Among 
these cases, 6 cases showed recurrence in 1 month, 6 cases in 2 months, 3 
case in 3 months, 1 case in 4 months, 1 case in 6 months, 1 case in 8 
months, 7 cases showed recurrence in 1 year, and 1 case in 2 yrs. 3 of the 
cases were late recurrences with previous tumour occurring in 3 yrs and 1 
case recurring after 7 years. (Table 14 and chart 12). 
TABLE : 14 - RECURRENCE IN TRANSITIONAL CELL 
CARCINOMAS 
Recurrence Number of cases Percentage 
1 month 6 20% 
2 month 6 20% 
3 month 3 10% 
4 month 1 3.3% 
6 month 1 3.3% 
8 month 1 3.3% 
1 year 7 23.4% 
2 year 1 3.3% 
3 year 3 10% 
7 year 1 3.4% 
Total 30 100% 
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RESULTS OF IMMUNOHISTOCHEMICAL STUDIES 
Of the total 101 transitional cell carcinomas, 50 cases of varying 
grade and stage were selected in a random manner and subjected to 
immunohistochemical analysis with a panel of 2 markers – CD 34 and 
HER-2/neu. The microvessel density was found out by using CD 34.  
Of the 50 cases, there were 42 males (84%) and 8 females (16%). The 
ages ranged between 35 and 81 yrs with a mean age of 60.28. There were 
3 cases (6%) of small biopsy, 44 cases of TURBT (88%), 2 cases (4%) of 
simple cystectomy and 1 case (2%) of radical cystectomy. There were 37 
cases (74%) below 66 years of age and 13 cases (26%) more than 66 
years. The tumour was located in the right lateral wall in 16 cases, left 
lateral wall in 13 cases, base in 4 cases, dome in 5 cases, posterior wall in 
1 case, entire bladder in 6 cases and the tumour is multiple in 5 cases. The 
tumours ranged in size from 0.5 to 8 cm with a mean size of 4.32. 
Among the final study group, 30 cases (60%) were low grade and 
20 cases (40%) were high grade. 45 cases (90%) showed papillary 
morphology and 5 cases (10%) showed flat morphology. Squamous 
metaplasia was seen in 9 cases (18%) and necrosis was seen in 8 cases 
(16%). Sarcomatoid area was seen in 1 case (2%). 8 cases (16%) 
belonged to stage Ta (non-invasive), 23 cases (46%) belonged to T1, 16 
cases (32%) belonged to T2a, 1 case (2%) belonged to T2b, 1 case (2%) 
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belonged to T3b and 1 case (2%) belonged to T4a. 8 cases (16%) 
belonged to stage 0, 23 cases (46%) belonged to stage 1, 17 cases (34%) 
belonged to stage 2 and 2 cases (4%) belonged to stage 3. 
Urine cytology was done in 12 cases and was found to be positive 
in 8 cases (66.7%) and negative in 4 cases (33.3%).Among the 50 cases, 
19 cases (38%) showed evidence of recurrence. 
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TABLE : 15 - DISTRIBUTION OF TRANSITIONAL CELL 
CARCINOMA AMONG THE VARIOUS CLINICOPATHOLOGICAL  
GROUPS FOR THE IHC STUDY (50 CASES) 
 
Clinico-pathological factor No. of cases (%) 
 
Age 
<66 37 (74%) 
>66 13 (26%) 
 
Sex 
Males 42 (84%) 
Females 8 (16%) 
 
 
Site 
Rt lateral wall 16 (32%) 
Lt lateral wall 13 (26%) 
Posterior wall 1 (2%) 
Base  4 (8%) 
Dome 5 (10%) 
Entire  6 (12%) 
Multiple  5 (10%) 
Size Mean size 4.32 
     Histological type Papillary  45 (90%) 
Non-papillary 5 (10%) 
Grade Low  30 (60%) 
High  20 (40%) 
 
 
Depth 
Ta 8 (16%) 
T1 23 (46%) 
T2a 16 (32%) 
T2b 1 (2%) 
T3b 1 (2%) 
T4b 1 (2%) 
Squamous metaplasia Present 9 (18%) 
Absent 41 (82%) 
Necrosis Present 8 (16%) 
Absent 42 (84%) 
Sarcomatous component Present 1 (2%) 
Absent 49 (98%) 
Stage 0 8 (16%) 
I 23 (46%) 
II 17 (34%) 
III 2 (4%) 
 Urine cytology Positive 8 (66.7%) 
Negative  4 (33.3%) 
Recurrence  present 19 (38%) 
 Absent 31 (62%) 
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In this study, various prognostic factors were compared with mean 
microvessel density and HER-2/neu expression. The microvessel density 
ranged from 8 to 102 with a mean value of 36.44. 22 cases (44%) showed 
strong expression for HER-2/neu (scoring 2+ and 3+) and were 
considered positive and 28 cases (56%) showed weak expression (scoring 
0+ and 1+) and were considered as negative  (Table 16 & Chart 13). 
TABLE : 16 - DISTRIBUTION OF HER-2/NEU EXPRESSION 
AND MICROVESSEL DENSITY IN TRANSITIONAL CELL 
CARCINOMA 
IHC parameters Result 
MVD Mean- 36.44 
HER-2/neu Positive-22(44%). 
Negative-28(56%) 
 
CORRELATION OF MICROVESSEL DENSITY WITH VARIOUS 
CLINICO – PATHOLOGICAL PARAMETERS 
In this study, the mean microvessel density for the male patients 
was found to be 38.45 with the standard deviation of 18.0.  The mean 
MVD for the female patients was found to be 25.88 with the standard 
deviation of 6.3. Since the standard deviation was found to be very high, 
the logarithmic transformations was carried out before applying the 
student’s t-test. The significant P-value infers that male patients have 
higher MVD than female patients (Table 17 and chart 14). 
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TABLE : 17 - CORRELATION OF GENDER WITH 
MICROVESSEL DENSITY 
Gender N 
Mean 
MVD 
Standard 
deviation(SD) 
t-
value* 
P-value 
Male 42 38.45 18.002 
2.047 
0.046 
 Female 8 25.88 6.379 
 For the logarithmic values of MVD the t-test has been applied. 
This study showed that there is no statistically significant correlation 
between MVD and site of tumour. Since only one patient had tumour at 
the posterior wall, for statistical purpose its MVD value was combined 
with that of the base. The mean values have been compared using 
ANOVA test. The non-significant p-value infers that the site of the 
occurrence of the tumour has no influence on the MVD level. (Table 18). 
TABLE : 18 - CORRELATION OF TUMOUR SITE WITH 
MICROVESSEL DENSITY 
Site N 
Mean 
MVD 
SD 
ANOVA F-
value* 
P-
value 
Right lateral wall 16 32.69 9.884 
0.472 0.795 
Left lateral wall 13 37.54 20.630 
Base & Posterior wall 5 40.40 18.756 
Dome 5 30.60 13.722 
Entire bladder 6 40.83 30.407 
Multiple 5 42.20 11.256 
 For the logarithmic values of MVD the ANOVA test has been 
applied. 
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This study showed increased mean MVD in patients with multiple 
tumours (42.2+17.8) when compared to patients having single tumours 
(35.8+17.8). However, this increase was found to be statistically 
insignificant. (Table 19 and chart 15) 
TABLE : 19 - CORRELATION OF TUMOUR NUMBER WITH 
MICROVESSEL DENSITY 
Number N Mean MVD SD t-value P value 
Single 45 35.80 17.801 
1.143 0.259 
Multiple 5 42.20 11.256 
 
In this study, out of 50 patients, 29 of them had tumour size less 
than or equal to 4 cms. Their mean MVD level was 38.1 with the standard 
deviation of 17.0. Remaining 21 patients had tumour size above 4 cms 
and their mean MVD level was 34.05. The non-significant p-value infers 
that MVD is independent of the tumour size. (Table 20). 
TABLE :  20 - CORRELATION OF TUMOUR SIZE WITH 
MICROVESSEL DENSITY 
Size N Mean MVD SD t-value P value 
<4 cm 29 38.17 17.046 
0.787 0.435 
>4 cm 21 34.05 17.735 
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This study showed mean MVD of 34.89+15.7 in case of papillary 
tumours and 50.4+25.9 in case of non-papillary tumours. This increase 
was found to be statistically significant. (Table 21 and chart 16). 
TABLE : 21 - CORRELATION OF HISTOLOGICAL TYPE WITH 
MICROVESSEL DENSITY 
Histological type N Mean MVD SD t-value P-value 
Papillary 45 34.89 15.712 
1.845 0.071 
Non- papillary 5 50.40 25.929 
 
This study showed an increase in MVD in high grade carcinoma 
patients (38.6+24.4) in comparison with low grade patients (35+10.5). 
However, this difference was not found to be statistically significant and 
hence MVD was not influenced by the grade of the tumour. (Table 22 and 
chart 17) 
TABLE : 22 - CORRELATION OF TUMOUR GRADE WITH 
MICROVESSEL DENSITY 
Grade N Mean MVD SD t-value P-value 
Low grade 30 35.00 10.518 
0.184 0.855 
High grade 20 38.60 24.356 
 
This study showed increased MVD in cases of superficial 
carcinomas (44.75+25.3) in comparison with infiltrative carcinomas 
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(34.86+15.2) and the increase in MVD in superficial carcinomas was not 
statistically significant. (Table 23) 
TABLE : 23 - CORRELATION OF INFILTRATION WITH 
MICROVESSEL DENSITY 
T stage N Mean MVD SD t-value P-value 
Superficial 8 44.75 25.336 
1.351 0.183 
Infiltrative 42 34.86 15.208 
 
This study showed mean MVD of 44.75+25.3 in stage 0 (non-
infiltrative) patients, 36.88+17.9 in stage I patients, 32.44+10.9 in stage II 
patients and 30+11.3 in stage III patients. Thus there was no increase in 
MVD in patients of increasing stage and this had no statistical 
significance. (Table 24 and chart 18) 
TABLE : 24 - CORRELATION OF TNM STAGE WITH 
MICROVESSEL DENSITY 
Stage N Mean MVD 
SD ANOVA –F 
value 
P-value 
0 8 44.75 25.336 
0.700 0.557 
I 23 36.88 17.858 
II 17 32.44 10.899 
III 2 30.00 11.314 
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In this study, the mean MVD in TCC with squamous metaplasia 
was 29+11.8 and in those without squamous metaplasia was 38+17.9. 
This increase in MVD was statistically significant. The mean MVD in 
TCC with necrosis was 28.5+11.6 and in those without necrosis was 
37.9+17.9. This increase in MVD was found to be statistically significant. 
The MVD in TCC with sarcomatoid component was 57 and the mean 
MVD in TCC without sarcomatoid component was 36+17.2. This 
decrease in value was not statistically significant (Table 25) 
TABLE : 25 - CORRELATION OF MICROVESSEL DENSITY 
WITH OTHER PARAMETERS 
Patient characteristics N Mean MVD SD t-value P-value 
Squamous 
metaplasia 
Present 9 29.00 11.758 1.820 0.075 
Absent 41 38.07 17.973 
Necrosis 
 
Present 8 28.50 11.588 1.844 0.071 
Absent 42 37.95 17.871 
Sarcomatoid 
component 
Present 1 57.00 - 1.265 0.212 
Absent 49 36.02 17.202 
 
This study showed an increase in mean MVD in patients with 
positive urine cytology (44+25.5) than that of patients with negative urine 
cytology (25.8+5.2). However, this increase in value was not found to be 
statistically significant.  (Table 26 and chart 19). 
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TABLE : 26 - CORRELATION OF URINE CYTOLOGY 
POSITIVITY WITH MICROVESSEL DENSITY 
Urine cytology N Mean MVD SD t-value P-value 
Positive 8 44.00 25.489 1.766 0.108 
Negative 4 25.75 5.188 
 
In this study, the patients with recurrence had an increased mean 
MVD value (39.9+18.4) than those without recurrence (33.9+16.3). 
However, this increase in MVD values was not statistically significant 
(Table 27 and chart 20).  
TABLE : 27 - CORRELATION OF TUMOUR RECURRENCE 
WITH MICROVESSEL DENSITY 
Recurrence N Mean MVD SD t-value P-value 
Present  19 41.73 18.409 1.333 0.189 
Absent  31 33.19 16.281 
 
The present study showed that there was statistically significant 
association between microvessel density and histological type, male 
gender and necrosis. Microvessel density was seen to increase with 
increasing number, grade, presence of sarcomatoid component, urine 
cytology positive tumours and in recurrent tumours. But when subjected 
to statistical analysis this association was not found to be significant. 
There was an increased expression in large tumours involving the entire 
bladder.  
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CORRELATION OF HER-2/NEU WITH VARIOUS 
CLINICOPATHOLOGICAL FACTORS 
In this study, the mean age of patients with positive HER-2/neu 
expression was 62.9+8.9 and the mean age of patients with negative 
HER-2/neu expression was 58.2+11. However, this increase in HER-
2/neu expression with age was not found to be statistically significant 
(Table 28). 
TABLE : 28 - CORRELATION OF AGE WITH HER-2/NEU 
EXPRESSION 
HER-
2/neu 
No. of 
subjects 
Mean age SD 
t-test 
value 
P-value 
Positive 22 62.95 8.904 
1.649 0.106 
Negative 28 58.18 11.046 
 
In this study, HER-2/neu positivity was noted in 45.2% of male 
patients and 37.5% of female patients. The non-significant p-value of the 
chi-square test shows that this association of increased HER-2/neu 
expression in males was not statistically significant (Table 29 and chart 
21). 
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TABLE : 29 - CORRELATION OF GENDER WITH HER-2/NEU 
EXPRESSION 
Gender 
HER-2/neu 
positive (%) 
HER-2/neu 
negative (%) 
Total 
Pearson chi 
square test 
P-
value 
Male 19 (45.2%) 23 (54.8%) 42 
0.163 
 
0.686 Female 3 (37.5%) 5 (62.5%) 8 
Total 22 (44%) 28 (58%) 50 
 
In the present study, HER-2/neu positivity was observed in 50% of 
tumours arising from the right lateral wall, 46.2% of tumours of left 
lateral wall, 1% of tumours of the dome, 0% in tumours of base and 
posterior wall, 4% in tumours involving the entire bladder and 3% in 
cases of multiple tumours. But this is statistically insignificant. Thus 
there is no difference in HER-2/neu  expression of tumours arising from 
different sites (Table 30). 
TABLE : 30 - CORRELATION OF TUMOUR SITE WITH HER-
2/NEU EXPRESSION 
Site 
HER-
2/neu 
positive 
HER-
2/neu 
negative 
Tota
l 
Pearson 
chi square 
test 
P-
valu
e 
Right lateral wall 8 (50%) 8 (50%) 16 
7.126 0.211 
Left lateral wall 6 (46.2%) 7 (53.8%) 13 
Base & Posterior wall 0 (0%) 5 (100%) 5 
Dome  1 (20%) 4 (80%) 5 
Entire  4 (66.7%) 2 (33.3%) 6 
Multiple  3 (60%) 2 (40%) 5  
Total 22 (44%) 28 (56%) 50  
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In this study, HER-2/neu positivity was noted in 42.2% of single 
tumours and 60% in cases of multiple tumours. However this increase in 
HER-2/neu expression was not found to be statistically significant (Table 
31 and Chart 22). 
TABLE : 31 - CORRELATION OF TUMOUR NUMBER WITH 
HER-2/NEU EXPRESSION. 
Number 
HER-2/neu 
positive 
HER-
2/neu 
negative 
Total 
Pearson chi 
square test 
P-value 
Single 19 (42.2%) 26 (57.8%) 45 
0.577 
 
0.447 Multiple 3 (60%) 2 (40%) 5 
Total         22 28 50 
 
This study showed 41.4% HER-2/neu positivity in tumours < 4 cm 
and 47.6% positivity in tumours > 4cm. However, this increase in HER-
2/neu positivity with size was not found to be statistically significant 
(Table 32).   
TABLE : 32 - CORRELATION OF TUMOUR SIZE WITH HER-
2/NEU EXPRESSION 
Size 
HER-2/neu 
positive 
HER-2/neu 
negative 
Total 
Pearson 
chi square 
test 
P-
value 
<4 cm 12 (41.4%) 17 (58.6%) 29 
0.192 0.661 >4 cm 10 (47.6%) 11(52.4%) 21 
Total 22 28 50 
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Among histological forms, 44.4% of papillary tumours and 40% of 
non-papillary tumours showed HER-2/neu positivity. However, this 
increase in HER-2/neu positivity in papillary tumours was not 
statiatically significant (Table 33 and Chart 23). 
TABLE : 33 - CORRELATION OF HISTOLOGICAL TYPE WITH 
HER-2/NEU EXPRESSION 
Histological 
type 
HER-
2/neu 
positive 
HER-
2/neu 
negative 
Total 
Pearson 
chi square 
test 
P-
value 
Papillary 
20 
(44.4%) 
25 (55.6%) 45 
0.036 0.849 
Non-papillary 2 (40%) 3 (60%) 5 
Total 22 28 50 
 
In this study, an increasing percentage of cases showing HER-
2/neu positivity in high grade tumours were observed. 30% of low grade 
tumours and 65% of high grade tumours showed positivity for HER-
2/neu. This association was found to be statistically significant (Table 34 
and Chart 24). 
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TABLE : 34 - CORRELATION OF TUMOUR GRADE WITH p53 
EXPRESSION 
Grade 
HER-2/neu 
positive 
HER-2/neu 
negative 
Total 
Pearson 
chi square 
test 
P-
value 
Low 9 (30%) 21 (70%) 30 
5.96 0.015 High 13 (65%) 7 (35%) 20 
Total 22 28 50 
  
In this study, an increase in HER-2/neu expression was seen in 
infiltrative tumours (47.6%) when compared to superficial tumours 
(25%). However, this association was not found to be statistically 
significant (Table 35). 
TABLE : 35 - CORRELATION OF INFILTRATION WITH HER-
2/NEU EXPRESSION 
T stage 
HER-2/neu 
positive 
HER-2/neu 
negative 
Total 
Pearson chi 
square test 
P-
value 
Superficial 2 (25%) 6 (75%) 8 
1.395 0.238 Infiltrative 20 (47.6%) 22 (52.4%) 42 
Total 22 28 50 
 
HER-2/neu positivity was noticed in 25% of stage 0 cases, 37.5% 
of stage I cases, 62.5% of stage II cases and 37.5% of Stage III cases. 
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There is increase in HER-2/neu expression with increase in stage except 
for stage III where there was only one HER-2/neu positive case and one 
HER-2/neu negative case. However, this association was not found to be 
statistically significant (Table 36 and Chart 25). 
TABLE : 36 - CORRELATION OF TNM STAGE WITH HER-
2/NEU EXPRESSION 
T stage 
HER-2/neu 
positive 
HER-2/neu 
negative 
Total 
Pearson 
chi square 
test 
P-
value 
0 2 (25%) 6 (75%) 8 
3.835 0.280 
I 9 (37.5%) 15 (62.5%) 24 
II 10 (62.5%) 6 (37.5%) 16 
III 1 (50%) 1 (50%) 2 
Total 22 28  
 
In this study, HER-2/neu positivity was noted in 33.3% of cases 
with squamous metaplasia, 62.5% cases with necrosis, 100% cases with 
evidence of sarcomatoid component. However, none of the values were 
found to be statistically significant using Pearson’s chi square test and the 
p-value was found to be >0.05 (Table37). 
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TABLE : 37 - CORRELATION OF HER-2/NEU WITH OTHER 
PROGNOSTIC PARAMETERS 
Patient characteristics 
HER-
2/neu 
positive 
HER-
2/neu 
negative 
Total 
Pearson chi 
square test 
P-
value 
Squamous 
metaplasia 
Present 3(33.3%) 6(66.7%) 9 0.507 0.477 
Absent 19(46.3%) 22(53.7%) 41 
Necrosis 
 
Present 5(62.5%) 3(37.5%) 8 1.323 0.250 
Absent 17(40.5%) 25(59.5%) 42 
Sarcomatoid 
component 
Present 1(100%) 0 1 1.299 0.254 
Absent 21(42.9%) 28(57.1%) 49 
 
In this study, HER-2/neu was positive in 75% of urine cytology 
positive tumours and 25%of urine cytology negative tumours. This 
increase in HER-2/neu expression in cases of positive urine cytology was 
found to be statistically significant. (Table 38 and chart 26). 
TABLE : 38 - CORRELATION OF URINE CYTOLOGY 
POSITIVITY WITH HER-2/NEU EXPRESSION 
Urine 
cytology 
HER-
2/neu 
positive 
HER-2/neu 
negative 
Total 
Pearson 
chi-square 
test 
P-
value 
Positive 6 (75%) 2 (25%) 8 
2.743 0.098 Negative 1 (25%) 3 (75%) 4 
Total 7 5 12 
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In this study, HER-2/neu expression was found to be positive in 
47.4% of recurrent tumours and 41.9 of non-recurrent tumours. However, 
this increase in HER-2/neu expression in recurrent tumours was not found 
to be statistically significant (Table 39 and chart 27). 
TABLE : 39 - CORRELATION OF TUMOUR RECURRENCE 
WITH HER-2/NEU EXPRESSION 
Recurrence 
HER-2/neu 
positive 
HER-2/neu 
negative 
Total 
Pearson chi 
square test 
P-value 
Yes 9 (47.4%) 10 (52.6%) 19 
1.032 0.310 No 13 (41.9%) 18 (58.1%) 31 
Total 22 28 50 
 
This study showed that there was a statistically significant 
association between HER-2/neu overexpression in case of high grade 
tumours and urine cytology positive tumours. There was an increased 
expression in male gender and multiple tumours. HER-2/neu over-
expression was seen to increase with increasing age, size, depth of 
infiltration, TNM stage, presence of necrosis, sarcomatoid component 
and in cases of recurrent tumours. But when subjected to statistical 
analysis this association was found to be statistically insignificant.  
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CORRELATION OF HER-2/NEU EXPRESSION WITH 
MICROVESSEL DENSITY 
 The mean MVD in HER-2/neu positive tumours was 36.95+22.4 
whereas the mean MVD in HER-2/neu negative tumours was 36.04+12.3. 
This minimal increase in MVD values in case of HER-2/neu positive 
tumours was not statistically significant and hence there is no difference 
in mean MVD values in tumours with variable HER-2/neu expression 
(Table 40 and chart 28). 
TABLE : 40 - MEAN MVD IN HER-2/NEU POSITIVE AND 
NEGATIVE TUMOURS 
HER-2/neu 
Number of 
cases 
Mean MVD 
SD t-value 
P-value 
Positive(%) 22 36.95 22.39 
0.434 
 
0.667 Negative(%) 28 36.04 12.32 
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TRANSITIONAL CELL CARCINOMA OF BLADDER- LOW GRADE 
 
FIGURE 3: Transitional cell carcinoma of bladder- papillary type 
 
TRANSITIONAL CELL CARCINOMA OF BLADDER- HIGH GRADE 
 
FIGURE 4: Transitional cell carcinoma of bladder involving entire bladder 
 
7149/11 
7933/11 
 
 
 
 
SQUAMOUS CELL CARCINOMA OF BLADDER 
 
FIGURE 5: Growth involving the entire bladder 
 
ADENOCARCINOMA OF BLADDER 
 
FIGURE 6: Multicentric growth within bladder 
1944/10
1101 
960/10 
 
 
 
 
PAPILLARY TRANSITIONAL CELL CARCINOMA- LOW GRADE 
  
 
 
 
 
 
PAPILLARY TRANSITIONAL CELL CARCINOMA- HIGH GRADE 
  
 
 
 
 
 
 
FIGURE 7: Low grade transitional 
cell carcinoma with cells arranged in 
papillary pattern (100X) HPE 7933/11 
 
FIGURE 8: shows 10 layers of epithelial 
cells with mild nuclear atypia. Umbrella 
cells are preserved (400X) HPE 7933/11 
 
FIGURE 9: High grade transitional cell 
carcinoma with cells arranged in papillary 
pattern (100X) HPE 5743/11 
FIGURE 10: Malignant epithelial cells 
showing loss of polarity, pleomorphism 
and prominent nucleoli (400X) HPE 
5743/11 
 
 
 
 
NON-PAPILLARY TRANSITIONAL CELL CARCINOMA 
  
 
 
 
 
 
INFILTRATION IN TRANSITIONAL CELL CARCINOMA 
  
 
 
 
 
 
 
FIGURE 11: Non papillary transitional 
cell carcinoma with cells arranged in solid 
sheets (100X) HPE 71/11 
FIGURE 12: shows a high grade neoplasm 
with nuclear pleomorphism, loss of polarity 
and loss of umbrella cells (400X) 71/11 
FIGURE 13: shows infiltration of 
transitional cell carcinoma into 
underlying submucosa (100X) HPE 
4868/11 
FIGURE 14: shows infiltration of 
malignant epithelial cells into underlying 
muscle layer (400X) HPE 4846/11 
 
 
 
 
OTHER PROGNOSTIC FACTORS 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
FIGURE 15: Squamous metaplasia (100X) 
HPE 6090/11 
FIGURE 16: Squamous metaplasia (400X) 
HPE 6090/11 
FIGURE 17: Necrosis (100X) 
HPE 6120/11  
FIGURE 18: Necrosis (400X) HPE 
6120/11  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
URINE CYTOLOGY POSITIVE IN TRANSITIONAL CELL CARCINOMAS 
  
 
 
 
 
 
FIGURE 19: Sarcomatoid component 
(100X) HPE 5743/11  
 
 
FIGURE 20: Sarcomatoid component 
(400X) HPE 5743/11  
 
 
 
FIGURE 21: Urine cytology showing 
clusters of malignant epithelial cells 
(100X) C-3397/11 
FIGURE 22: Malignant cells showing 
nuclear atypia and hyperchromatic 
nuclei (400X) C-3397/11 
 
 
 
 
HIGH MICROVESSEL DENSITY 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
FIGURE 23: Transitional cell 
carcinoma of bladder- high grade 
showing high microvessel density- 102 
vessels. (200X) HPE 6516/11 
FIGURE 24: Transitional cell carcinoma 
of bladder- high grade showing high 
microvessel density- 95 vessels. (200X) 
HPE 165/11 
FIGURE 25: Transitional cell carcinoma 
of bladder- low grade showing high 
microvessel density- 51 vessels. (200X) 
HPE 1093/10 
FIGURE 26: Transitional cell 
carcinoma of bladder- low grade 
showing high microvessel density- 48 
vessels. (200X) HPE 6928/10 
 
 
 
 
LOW MICROVESSEL DENSITY 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
FIGURE 29: Transitional cell carcinoma 
of bladder- low grade showing low 
microvessel density- 22 vessels. (200X) 
HPE 10329/11 
FIGURE 30: Transitional cell 
carcinoma of bladder- low grade 
showing low microvessel density- 21 
vessels. (200X) HPE 10331/11 
FIGURE 27: Transitional cell carcinoma 
of bladder- high grade showing low 
microvessel density- 15 vessels. (200X) 
HPE 1882/11 
FIGURE 28: Transitional cell carcinoma of 
bladder- high grade showing low 
microvessel density-23 vessels. (200X) HPE 
9467/10 
 
 
 
 
HER-2/neu NEGATIVE (0) 
  
 
 
 
 
 
 
 
 
HER-2/neu NEGATIVE (1+) 
  
 
 
 
 
FIGURE 31: Transitional cell carcinoma 
of bladder- low grade showing no 
staining. (100X) HPE 8813/11 
FIGURE 32: Transitional cell carcinoma 
of bladder- low grade showing no 
staining. (400X) HPE 8813/11 
FIGURE 33: Transitional cell carcinoma 
of bladder- low grade showing weak 
staining in part of membrane of less than 
10% of the cells staining. (100X) HPE 
9719/11 
 
FIGURE 34: Transitional cell carcinoma of 
bladder- low grade showing weak staining 
in part of membrane of less than 10% of the 
cells staining. (400X) HPE 9719/11 
 
 
 
 
 
 
HER-2/ neu POSITIVE (2+) 
   
 
 
 
 
 
 
 
 
HER-2/ neu POSITIVE (3+) 
  
 
 
 
 
FIGURE 35: Transitional cell carcinoma 
of bladder- high grade showing complete 
membranous staining of moderate 
intensity in >10% of tumor cells. (100X) 
HPE 8596/10 
 
 
FIGURE 36: Transitional cell carcinoma 
of bladder- high grade showing complete 
membranous staining of moderate 
intensity in >10% of tumor cells. (400X) 
HPE 8596/10 
 
 
 
FIGURE 37: Transitional cell carcinoma 
of bladder- high grade showing strong 
complete membranous staining in more 
than 10 % of tumor cells. (100X) HPE 
7219/11 
 
 
 
FIGURE 38: Transitional cell carcinoma 
of bladder- high grade showing strong 
complete membranous staining in more 
than 10 % of tumor cells. (400X) HPE 
7219/11 
 
 
 
 
 
 
 
 
DISCUSSION 
Bladder cancer is the sixth most common malignancy in developed 
countries.
(1,3) 
It ranks as the fourth and ninth most frequently diagnosed 
cancer in men and women, respectively, in the United States.
(1)
 The 
incidence of bladder cancer in India is 3.2% in males and 0.7% in 
females.
(87) 
Though grade and stage are considered to be the best prognostic 
markers for bladder carcinoma, additional prognostic information is given 
by certain biologic markers. Microvessel density and HER-2/neu were 
considered as important markers which were correlated with other 
prognostic markers in various studies and give additional information. 
In the present study, immunohistochemical evaluation was done in 
50 cases of transitional cell carcinomas of bladder and an attempt was 
made to correlate the microvessel density and HER-2/neu expression with 
the known prognostic factors of bladder cancers and with recurrence.  
Madras Medical College being a tertiary referral centre, about 
0.57% of bladder carcinomas and 0.51% of TCCs were reported among 
the specimens received in the year 2010 and 2011. Among the bladder 
specimens received, 81.1% were malignant tumours.  
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The common tumour in bladder in this study was transitional cell 
carcinoma (88.6%) which is nearer to the study by Matalka et al
(91) 
 and 
Khaled El Gehani et al.
(92) 
However, the percentage of squamous cell 
carcinoma and adenocarcinoma were more in this study (Table 41). 
TABLE : 41 - COMPARISON OF DISTRIBUTION OF 
HISTOLOGICAL TYPES OF BLADDER CARCINOMA 
Histological type 
Matalka et 
al
(93) 
Khaled El Gehani 
et al
(92) 
Current 
study 
Transitional cell 
carcinoma 
95.7% 92.8% 88.6% 
Adenocarcinoma  2.6% 2.4% 6.1% 
Squamous cell 
carcinoma 
1.7% 2.4% 5.3% 
TCC and SCC - 2.4% - 
 
This study showed that the highest incidence of transitional cell 
carcinomas occurred in 61 to 70 year age group. The age of transitional 
cell carcinoma patients ranged from patients 22 years to 82 years with the 
mean age of 58.74 years. This had a concurrence with the study done by 
Mohammad Reza Jalali Nadoushan et al
(88)
 and Surendra B Kolla et al
(89)
 
(Table 42). 
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TABLE : 42 - COMPARISON OF MEAN AGE IN 
TRANSITIONAL CELL CARCINOMAS OF BLADDER 
Studies 
Mohammad Reza Jalali 
Nadoushan et al
(88) 
Surendra B 
Kolla et al
(89) 
Current 
study 
Mean age(yrs) 56.3 58 58.74 
 
The male:female ratio is 8:1 which was close to the study 
conducted by Matalka I et al
(90)
 (9:1). The most common site of 
transitional cell carcinoma of bladder in this study was the right lateral 
wall (37.7%) followed by left lateral wall (29.8%). This was almost 
similar to the study by William T. Stephenson et al
(93)
 who also showed 
the predominance of tumours arising from the lateral walls.  
This study showed 6% of multiple tumours which was lower than 
the study by Igor Frank et al
(94)
 and L. Santos et al
(95)
 who showed the 
incidence of multiple tumours to be 14%and 12% respectively. In this 
study, the mean size of tumour was 4.1cm which showed concurrence 
with the study conducted by Igor Frank et al(4.1).
(94) 
 In this study, papillary tumours were more common than the non-
papillary(solid) tumours which was in concurrence with the study 
conducted by Thomas Quentin et al.
(96)
 (Table 43) 
70
 
 
 
 
TABLE : 43 - COMPARISON OF HISTOLOGICAL TYPE OF 
TRANSITIONAL CELL CARCINOMAS OF BLADDER 
Histological type Thomas Quentin et al
(96)
 Current study 
Papillary 73.2% 82.2% 
Non-papillary 26.8% 17.8% 
 
In the present study, low grade tumours were more common. This 
was in concurrence with the study conducted by Matalka I et al.
(91) 
(Table 
44). 
TABLE : 44 – COMPARISON OF GRADE OF TUMOUR 
Grade 
Matalka I et 
al
(91) 
Ali Canoglu et 
al
(97) Current study 
Low grade 60% 44.1% 73.3% 
High grade 40% 31.2% 26.7% 
PUNLMP - 24.7% - 
 
This study showed a higher proportion of T1 tumours followed by 
Ta tumours similar to the study by Eun Yong Choi et al.
(98) 
However this 
did not concur with the studies by others who showed a predominance of 
tumours of other stage  (Table 45). 
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TABLE : 45 - COMPARISON OF DEPTH OF TUMOUR 
Depth 
of 
tumour 
Matalka 
I et al
(91) 
Igor 
Frank 
et al
(94) 
Thomas 
Quentin 
et al
(96) 
Sari A 
et al
(99) 
Eun 
Yong 
Choi 
et al
(98) 
Current 
study 
Ta 54.5% 1.9% 59.2% 13.7% 12.9% 29.7% 
T1 17.3% 2.6% 5.6% 15.7% 50% 40.6% 
T2 20% 31.3% 31% 21.6% 14.5% 25.7% 
T3 7.3% 51.9% 4.2% 33.3% 11.3% 1% 
T4 0.9% 12.3% - 15.7% 11.3% 3% 
 
This study showed most of the cases in stage 1 which is concurrent 
with the study conducted by Khaled El Gehani et al
(88)
 and E.A. Philp et 
al
(95)
(Table 46). 
TABLE : 46 - COMPARISON OF STAGE OF INFILTRATIVE 
TUMOURS 
Stage 
Khaled El Gehani        
et al
(92)
 
E.A. Philp et al
(99) 
Current study 
1 71.4% 59.3% 57.7% 
2 26.2% 14.2% 36.6% 
3 2.4% 15% 5.7% 
4 - 11.5% - 
 
This study showed a recurrence of 29.7% which was concurrent 
with the study done by Matalka I et al
(91)
 in Jordan, Asia. However, 
studies by Rawaa G Al-Tereihi et al
(104)
 which was done in Iraq, Asia 
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showed increased recurrence rate of 58.33% (Table 47). This study 
showed that many of the recurrent tumours presented with lower stage. 
Hence other prognostic factors like microvessel density and HER-2/neu 
expression assumed clinical significance. 
TABLE : 47 - COMPARISON OF RECURRENCE OF TUMOUR 
Recurrence 
Rawaa G Al-Tereihi 
et al
(104) 
Matalka I et 
al
(91) 
Current 
study 
Present 58.33% 31.4% 29.7% 
Absent 41.67% 68.6% 70.3% 
 
TABLE : 48 - COMPARISON OF MEAN MICROVESSEL 
DENSITY WITH WORLD STATISTICS 
Studies 
Grade Infiltration Stage 
Recurrence/ 
progression 
Low High Present Absent 1 2 3 Present Absent 
Eun Yong 
Choi et al98) 
94.5 109.5 - - - - - 131.1 94.5 
Khaled El 
Gehani et 
al(92) 
65.8 106.3 - - 72.1 104.8 86.6 - - 
N.E.Stavropo
ulos et al(101) 
20.8 16.4 20.73 17.58 - - - 19.61 19.1 
E.A. philp et 
al(100) 
47.7 51.8 - - 46.19 53.90 52.2 - - 
C.K.Hawke et 
al(105) 
77.4 90.8 - - - - - - - 
Jonathan C. 
Goddard et 
al(106) 
75.8 81.3 65.6 85.5 - - - - - 
AliCanoglu et 
al(97) 
90.4 95.7 88.9 94.0 - - - 92.7 87.4 
Current study 35.0 38.6 44.8 34.9 36.9 32.4 30.0 39.9 33.9 
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CORRELATION OF MICROVESSEL DENSITY WITH KNOWN 
CLINICO-PATHOLOGICAL PROGNOSTIC FACTORS 
 
E.A. Philp et al (1996) studied 113 cases of transitional cell 
carcinoma of bladder and demonstrated statistically significant 
association between MVD and tumour stage and with prognosis.
(100) 
C.K.Hawke et al (1998) studied 42 cases of transitional cell 
carcinomas and found a statistically significant association between MVD 
and survival of patients. Though the mean MVD was increased with 
increasing grade and stage, the correlation was not statistically 
significant.
(105) 
Eun Yong Choi et al (1999) studied 67 cases of transitional cell 
carcinomas of bladder and found no correlation between MVD with stage 
or grade of the tumour. However they found a significant association with 
tumour progression.
(98) 
 
L. Santos et al (2003) studied 66 superficial papillary carcinomas 
and found that MVD was an independent prognostic factor for 
recurrence.
(95) 
 Jonathan C. Goddard et al (2003) studied 180 cases of TCCs and 
found a statistically significant correlation between MVD with stage and 
74
 
 
 
 
progression of the tumour. Though the mean MVD was increased in high 
grade tumours, the association was not statistically significant.
(106) 
 
AliCanoglu et al (2004) studied 43 superficial TCCs and 34 
invasive TCCs and found statistically significant correlation between 
MVD and stage, grade, infiltration and tumour progression and 
recurrence.
(97) 
 
N.E.Stavropoulos et al (2004) studied 127 cases of superficial 
bladder carcinomas and showed that there was no significant association 
of MVD with stage, grade and recurrence.
(101) 
Khaled El Gehani et al (2005) studied 42 cases of bladder 
carcinomas and found statistically significant association of MVD with 
tumour grade and stage and it was not affected by age and sex of the 
patients. 
In comparison with the above studies, this study showed an 
increase in MVD in high grade and in recurrent tumours, but this 
association was not found to be statistically significant. This study 
showed decreasing MVD with stage of the tumour, with infiltration and 
with size which was statistically insignificant. The MVD values were also 
increased in multiple tumours, tumours with sarcomatoid component and 
in tumours with positive urine cytology. But these values were also 
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statistically insignificant. MVD values showed statistically significant 
increase in male gender and in non-papillary (solid) tumours.  
Though this study showed a decrease in mean MVD with 
increasing stage of the tumour, it can be seen that patients presenting with 
high MVD (>50) were presenting with recurrence even when they present 
in lower stage and HER-2/neu negative. Hence, more patients presenting 
with early stage need to be evaluated for MVD and closely followed up 
for possible recurrence. 
 One case with a maximum MVD of 102 was an early stage Ta 
tumour presenting for the first time showed positive HER-2/neu status. 
Since the MVD values were high, a close follow-up of this patient for 
recurrence could assume greater clinical significance.  
TABLE : 49 - COMPARISON OF HER-2/NEU EXPRESSION 
WITH WORLD STATISTICS 
Studies HER-2/neu 
positive 
HER-2/neu 
negative 
Mohammad Reza Jalali 
Nadoushan et al
(88) 
37.3% 62.7% 
Donna E. Hansel et al
(102) 
36% 64% 
Surendra B. Kolla et al
(89) 
55.6% 44.4% 
Aurora alexa et al
(103) 
35.6% 64.4% 
Rawaa G Al-Tereihi et al
(104) 
41.6% 58.4% 
Khaled El Gehani et al
(92) 
59% 41% 
Current study 44% 56% 
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CORRELATION OF HER-2/NEU EXPRESSION WITH KNOWN 
CLINICO-PATHOLOGICAL PROGNOSTIC FACTORS 
 
 Mohammad Reza Jalali Nadoushan et al (2007) assessed 75 cases 
of transitional cell carcinomas of bladder and found a definitive 
association between HER-2/neu expression and grade of the tumour.
(88) 
  Donna E. Hansel et al (2008) examined 53 invasive high-grade 
urothelial carcinomas and demonstrated that HER-2/neu targeted therapy 
can be useful for metastatic lesions.
(102) 
 Surendra B. Kolla et al (2008) examined 90 cases of invasive 
transitional cell carcinoma of the urinary bladder and demonstrated that 
HER-2/neu expression is associated with advanced bladder cancer and 
influences disease progression in these patients.
(89) 
 
Aurora alexa et al (2010) studied the expression of HER-2/neu in 
59 cases of urothelial carcinomas and demonstrated statistically 
significant correlation with tumour grade. However, HER-2/neu 
expression was not correlated with tumour stage.
(103) 
 
Rawaa G Al-Tereihi et al (2011) studied 60 cases of bladder 
carcinoma and demonstrated statistically significant association between 
HER-2/neu expression with grade and stage of bladder carcinoma. 
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However the association between HER-2/neu expression and recurrence 
was not statistically significant.
(104) 
 
Khaled El Gehani et al (2011) studied 39 cases of bladder 
carcinoma and demonstrated statistically significant correlation between 
HER-2/neu expression with tumour stage. However, though the 
expression of HER-2/neu was more frequent in high-grade than in low-
grade carcinomas, but the difference was not statistically significant. 
Patients’ age and sex were not related to HER-2 over expression.(92) 
 In comparison with the above studies, this study showed a 
statistically significant association between HER-2/neu expression and 
grade of the tumour. This study also showed a statistically significant 
association between HER-2/neu and urine cytology positivity. Though 
this study showed increased HER-2/neu expression in older age group, 
male gender, multiple tumours, increasing size and stage, necrosis, 
sarcomatoid component and recurrence, statistically significant 
association could not be ascertained. This study also showed an increased 
HER-2/neu expression in papillary tumours when compared to non-
papillary tumours which was not statistically significant. 
 Among the 7 cases of recurrence with high MVD (>50), 5 cases 
were negative for HER-2/neu expression. More studies are required to 
assess if there is any inhibitory effect of HER-2/neu over-expression on 
microvessel density. 
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SUMMARY 
 The percentage of bladder carcinomas among the 19898  surgical 
samples received at Madras Medical College in the year 2010 and 
2011 is 5.7%. 
 The distribution of non-neoplastic bladder lesions was 20.9% and 
malignant tumours were 81.1%. 
 Transitional cell carcinomas were the most common carcinoma of 
bladder constituting 88.6% of cases. 
  Transitional cell carcinomas had a peak incidence in the age group 
of 61 – 70 years. The mean age of presentation is 58.74 yrs. 
 78.2% of transitional cell carcinomas occur in males and 21.8% in 
females. 
 The most common location of transitional cell carcinoma was at 
the right lateral wall which constituted about 37.7% of the cases. 
 94% of transitional cell carcinomas were single and 6% were 
multiple. 
 The mean size of transitional cell carcinomas was 4.1 cm. 
 Papillary tumours constituted 82.2% of cases and solid tumours, 
17.8% of cases. 
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 Low grade urothelial carcinomas were more common accounting 
for 73.3% of cases.  
 70.3% of tumours were infiltrative and 29.7% were superficial 
tumours. 
 40.6% tumours presented in T1 stage (invasion upto lamina 
propria). 
 Most of the tumours presented in stage 1(40.6%). 
 Squamous metaplasia was present in 14.9% of cases, necrosis in 
18.8% of cases and sarcomatoid component in 3% of cases. 
 Urine cytology was positive in 58.3% of cases. 
 Recurrence was present in 29.7% of cases. 
 The mean microvessel density was 36.44. 
 The mean MVD values showed statistically significant increase in 
case of male gender, non-papillary tumours and in TCCs with 
necrosis. 
 The mean MVD values showed an increase in multiple tumours, 
high grade, in tumours with sarcomatoid component, positive urine 
cytology and in recurrent tumours. However they were statistically 
insignificant. 
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 The mean MVD values showed a decrease with increasing stage, 
size and infiltration and this association was statistically 
insignificant. 
 Though MVD values were reducing with stage, patients with high 
microvessel density (>50) presented with recurrence. 
 HER-2/neu expression was seen in 44% of cases. 
 Statistically significant association was found between HER-2/neu 
expression and grade and urine cytology positive tumours. 
 HER-2/neu expression was increased in older patients, males, 
multiple tumours, tumours with increased size, stage, infiltration, 
necrosis, sarcomatoid component, necrosis and in recurrent 
tumours but these were statistically insignificant. 
 HER-2/neu expression was increased in papillary tumours than 
non-papillary tumours, but this had no statistical significance. 
 The mean MVD values were increased in HER-2/neu positive 
tumours but this was not statistically significant. 
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CONCLUSION 
The incidence of bladder carcinoma was lower in this study group 
than the western population. Many patients presented in older age with a 
mean age of 58.74 with predominance in males. However, there was an 
increase in squamous cell carcinomas and adenocarcinomas in the study. 
This study also showed a reduced rate of recurrence than the western 
population. The mean microvessel density was found to be 36.44 and 
HER-2/neu expression was seen in 44% of the cases.  
An increased HER-2/neu expression was noted in older patients, 
male gender, multiple tumours, recurrent tumours, increasing size, stage, 
infiltration and in the presence of necrosis and sarcomatous component, 
but was not statistically significant. HER-2/neu showed an increased 
expression in papillary tumours with no statistical significance. Both 
microvessel density and HER-2/neu expression were increased in cases of 
recurrent tumours which was not statistically significant. There is no 
statistically significant difference in microvessel density of HER-2/neu 
positive and negative tumours. 
Microvessel density had a statistically significant association with 
necrosis, non-papillary tumours and in male gender. HER-2/neu 
expression showed statiscally significant association with grade and urine 
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cytology positivity. An increased microvessel density was noted in 
multiple, high grade, recurrent, positive urine cytology tumours and in 
tumours with sarcomatous component which was statistically 
insignificant. The values were reduced with increasing stage, size and 
infiltration which was not found to be statistically significant. 
In this study, though MVD was found to decrease with stage, the 
patients with high MVD values i.e >50 were presenting with recurrence. 
Also many of the recurrent tumours presented in early stage. Hence more 
patients presenting with early stage tumour for the first time need to be 
evaluated for MVD and closely followed up for possible recurrence. Thus 
a larger sample size will help in identifying the association between the 
stage, MVD status and recurrence to formulate treatment strategies and 
possible targeted therapy. 
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1 4868/11 35 F TURBT 4 Dome TCC Y Low P A A A A T1 I 28 1 C-1693/11 Neg 
2 4846/11 80 M TURBT 3 Rt lat wall TCC Y Low P A A A A T2A II 48 2   
3 4963/11 55 M TURBT 6 Rt lat wall TCC Y Low P A A A P-2008 T1 I 38 2   
4 5743/11 62 M TURBT 4 Multiple TCC Y High P A A P P-6mon T2A II 57 2 C-2157/11 Pos 
5 5746/11 78 M TURBT 5 Rt lat wall TCC Y Low P A A A A T2A II 29 3   
6 6090/11 67 M TURBT 4 Lt lat wall TCC Y High P P P A A T1 I 8 2   
7 6120/11 43 M TURBT 7 Entire TCC Y High P P P A A T1 I 32 1   
8 5211/11 60 M TURBT 5 Pos wall TCC Y Low P A A A A T1 I 37 1 C-1901/11 Pos 
9 4762/11 60 M TURBT 4 Lt lat wall TCC Y High P A P A P-2mon T1 I 35 3   
10 5541/11 65 M TURBT 3 Multiple TCC Y High P A A A P-8mon T1 I 43 3   
11 6516/11 67 M TURBT 7 Entire TCC Y High A A A A A TA 0 102 2 C-2339/11 Pos 
12 7149/11 55 M Rad cyst 8 Entire TCC Y High P A P A A T4A III 22 3 C-2316/11 Pos 
13 7933/11 51 M Rad cyst 5 Rt lat wall TCC Y Low P A A A A T2A II 23 2   
14 6620/11 65 M TURBT 3 Rt lat wall TCC Y High P P A A A T1 I 26 0   
15 7770/11 56 M TURBT 1.5 Lt lat wall TCC Y Low A A A A P-2008 TA 0 37 1   
16 7559/11 68 M TURBT 6 Rt lat wall TCC Y High P P A A P-1mon T2A II 43 1   
17 2341/11 60 M TURBT 6 Rt lat wall TCC Y High P A A A P-12mon T1 I 55 1   
18 1882/11 45 F TURBT 0.5 Dome TCC Y High P A A A A T1 I 15 0   
19 3258/11 59 M TURBT 3 Base TCC Y Low A A A A P-2mon TA 0 53 1   
20 3311/11 81 M TURBT 2 Multiple TCC Y Low A A A A A TA 0 48 1   
21 3738/11 75 M TURBT 3 Multiple TCC Y Low P P A A A T2A II 28 1   
22 13/11 65 M TURBT 4 Base TCC Y High P A A A P-3mon T1 I 65 0   
23 71/11 54 M Small bx 5 Dome TCC N High P A A A P-1mon T1 I 36 0   
 
 
 
 
24 1151/11 47 F TURBT 2 Lt lat wall TCC Y Low P A A A A T1 I 35 1   
25 1510/11 61 M TURBT 3 Lt lat wall TCC Y Low P A A A P-3mon T1 I 55 1   
26 8736/11 59 M TURBT 3 Rt lat wall TCC Y Low A A A A P-2mon TA 0 32 0   
27 8813/11 46 M TURBT 6 Base TCC Y Low P A A A A T1 I 18 0 C-3366/11 Neg 
28 8922/11 65 M TURBT 7 Entire TCC Y Low P A A A A T2A II 35 3 C-3397/11 Pos 
29 9538/11 65 F TURBT 5 Base TCC Y Low P A A A A T2A II 29 1 C-3662/11 Neg 
30 9719/11 57 M TURBT 5 Lt lat wall TCC Y Low P A A A A T1 I 32 1   
31 10074/11 68 M TURBT 8 Lt lat wall TCC Y Low P A A A A T1 I 32 1   
32 10329/11 51 M TURBT 3 Rt lat wall TCC Y Low A A A A P-1mon TA 0 22 1   
33 10331/11 57 M TURBT 4 Lt lat wall TCC y Low P A A A P-2mon T2A II 21 2   
34 6241/11 65 M TURBT 6 Entire TCC y Low P P A A A T1 I 31 3 C-2285/11 Pos 
35 7219/11 65 M TURBT 5 Lt lat wall TCC Y High P A A A A T2A II 30 3 C-2562/11 Pos 
36 165/11 50 M TURBT 4 Lt lat wall TCC N High P A A A P-3mon T1 I 95 3   
37 1580/10 70 M TURBT 3 Multiple TCC Y High P A A A A T1 I 35 3   
38 1096/10 55 M TURBT 2 Lt lat wall TCC Y Low P A A A A T1 I 30 2   
39 6928/10 75 M TURBT 3 Lt lat wall TCC Y Low P P P A A T2A II 48 1   
40 965/10 58 M TURBT 4 Lt lat wall TCC Y Low P A A A A T1 I 30 1   
41 1048/10 45 F TURBT 4 Rt lat wall TCC N High P A P A P-2009 T2A II 32 2   
42 1093/10 47 M TURBT 3 Dome TCC N Low P A A A A T1 I 51 1   
43 1380/10 68 F Simp cyst 6 Dome TCC Y High P A A A P-2009 T2A II 23 2   
44 8725/10 65 M TURBT 2 Rt lat wall TCC N Low P A A A A T3B III 38 1 C-2946/10 Pos 
45 7741/10 45 F Rad cyst 7 Entire TCC Y Low P A A A P-1mon T2B II 23 1   
46 3880/10 70 M TURBT 3 Rt lat wall TCC Y Low A A A A A TA 0 38 1   
47 8596/10 64 M Small bx 4 Rt lat wall TCC Y Low A A A A A TA 0 26 2   
48 9467/10 49 M TURBT 6 Rt lat wall TCC Y High P P P A A T2A II 23 1   
49 6759/10 75 M TURBT 3 Rt lat wall TCC Y High P A P A P-2009 T2A II 28 3 C-2335/10 Neg 
50 5061/10 66 F TURBT 6 Rt lat wall TCC Y High P P A A A T2A II 22 2   
51 2351/11 60 M TURBT 5 Pos wall TCC N Low P A A A A T1 I     
 
 
 
 
52 2353/11 58 M TURBT 4 Lt lat wall TCC Y Low P A A A P-2010 T1 I     
53 2625/11 80 M TURBT 2 Rt lat wall TCC Y Low P A A A A T1 I     
54 2907/11 54 M TURBT 2 Rt lat wall TCC Y Low A A A A A TA 0     
55 4719/11 35 M Small bx 5 Rt lat wall TCC Y Low A P P A A TA 0     
56 4842/11 55 F TURBT 3 Pos wall TCC Y Low A A A A P-2009 TA 0     
57 3943/11 62 F TURBT 4 Rt lat wall TCC Y Low P A A A A T1 I     
58 4527/11 64 F TURBT 3 Pos wall TCC Y Low A A A A A TA 0     
59 158/10 65 F TURBT 3 Rt lat wall TCC Y Low P A A A A T1 I   C-3308/09 Pos 
60 2446/10 52 M TURBT 4 Lt lat wall TCC Y Low P P A A A T1 I     
61 2552/10 70 M TURBT 3 Multiple TCC Y Low A A P A A TA 0   C-899/12 Neg 
62 2808/10 45 F TURBT 4 Rt lat wall TCC Y Low A A A A A TA 0   C-997/10 Pos 
63 2825/10 45 M Rad cyst 7 Entire TCC N Low P A A A P-2mon T2A II     
64 2863/10 65 M TURBT 3 Lt lat wall TCC Y Low A A A A A TA 0   C-1018/10 Neg 
65 3106/10 22 M TURBT 4 Lt lat wall TCC Y High P A A A A T1 I     
66 3434/10 47 M TURBT 3 Base TCC Y Low A A P A A TA 0     
67 3547/10 60 M TURBT 4 Rt lat wall TCC N High P A P A A T2A II     
68 3673/10 65 F Small bx 2 Dome TCC Y Low A A A A A TA 0     
69 3971/10 65 M Small bx 4 Rt lat wall TCC N Low P A A A A T1 I   C-1317/10 Pos 
70 4035/10 73 F TURBT 6 Entire TCC Y Low P A A A A T1 I     
71 4155/10 33 M TURBT 0.5 Rt lat wall TCC N Low A A P A A TA 0     
72 4288/10 65 F TURBT 6 Rt lat wall TCC N Low A A A A A TA 0     
73 4374/10 51 M TURBT 3 Base TCC Y Low P A A A A T1 I     
74 4455/10 62 M Rad cyst 4 Rt lat wall TCC Y High P A A A P-2009 T2B II     
75 4687/10 78 M TURBT 3 Lt lat wall TCC N Low A A A A A TA 0     
76 5038/10 47 F Rad cyst 3.5 Rt lat wall TCC N Low P A P A P-2mon T2A II     
77 5336/10 82 M TURBT 4 Lt lat wall TCC Y Low P A A A A TI I   C-1741/10 Pos 
78 3571/10 46 F TURBT 4 Rt lat wall TCC N High P P P A A T1 I     
79 6267/10 34 M Rad cyst 5 Lt lat wall TCC Y Low P A A A A T1 I     
 
 
 
 
80 6439/10 65 F TURBT 3 Dome TCC Y Low A A A A A TA 0     
81 6716/10 75 M TURBT 3 Lt lat wall TCC Y Low A A A A A TA 0     
82 7534/10 49 M Rad cyst 6 Rt lat wall TCC Y Low P P P A P-1mon T2A II     
83 7838/10 67 M Small bx 5 Rt lat wall TCC Y Low A A A P A TA 0   C-2680/10 Pos 
84 9132/10 60 M TURBT 3 Lt lat wall TCC Y Low A A A A A TA 0     
85 348/11 56 M Small bx 4 Rt lat wall TCC Y Low A A A A A TA 0     
86 474/11 60 F TURBT 2.5 Rt lat wall TCC Y Low P A A A P-4 mon T1 I   C-105/11 Neg 
87 567/11 72 M TURBT 2 Rt lat wall TCC Y Low P A A A P-2004 T1 I   C-168/11 Neg 
88 610/11 40 F TURBT 4 Lt lat wall TCC N Low P A P A A T2A II     
89 1399/11 75 M TURBT 5 Rt lat wall TCC N Low P A P A A T2A II   C-463/11 Pos 
90 1614/11 79 M TURBT 4.5 Lt lat wall TCC N High P A A A A T1 I     
91 1036/11 45 M TURBT 2 Lt lat wall TCC Y Low A A A A A TA 0     
92 7769/11 60 M TURBT 2 Rt lat wall TCC Y Low A A A A A TA 0   C-2897/11 Neg 
93 8175/11 31 M TURBT 1 Lt lat wall TCC Y Low A A A A A TA 0     
94 8473/11 80 M TURBT 5 Rt lat wall TCC Y Low A P A A P-1 mon TA 0     
95 8804/11 58 M TURBT 6 Lt lat wall TCC Y Low P A P A P-3yrs T1 I     
96 8910/11 32 M TURBT 3 Lt lat wall TCC Y Low A A A A A TA 0     
97 9007/11 52 M TURBT 4 Lt lat wall TCC Y Low P A A A P-1yr T1 I   C-3338/11 Neg 
98 9838/11 65 M Small bx 7 Entire TCC Y Low P A A A A T4A III     
99 9841/11 65 M Small bx 6 Lt lat wall TCC Y Low P A A A A T4A III     
100 5932/11 42 F TURBT 4 Rt lat wall TCC Y Low P P A A A T2A II     
101 5999/11 51 M Rad cyst 10 Entire Sa Ca N _ P _ _ _ A T2B II     
 
 
 
 
KEY TO MASTER CHART 
 
Proc                  - Procedure done 
Pap                   - Papillary pattern 
Infil                  - Infiltration 
Sq meta            - Squamous metaplasia 
Nec                   - Necrosis 
Sa com            - Sarcomatoid component 
Rec                  - Recurrence 
MVD               - Miicrovessel density 
Malig               - Malignancy 
M                     - Male 
F                      - Female 
TURBT           - Transurethral resection of bladder tumour 
Rad cyst          - Radical cystectomy 
Small bx         - Small biopsy 
Simple cyst    - Simple cystectomy 
Rt lat wall      - Right lateral wall 
Lt lat wall      - Left lateral wall 
Pos wall        - Posterior wall 
TCC              - Transitional cell carcinoma 
Y                   - Yes 
N                   - No 
P                    - Present 
A                   - Absent 
Pos                - Positive 
Neg               - Negative  
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ANNEXURE I 
WHO CLASSIFICATION OF BLADDER CARCINOMAS 
UROTHELIAL TUMOURS 
Infiltrating urothelial carcinoma  
    with squamous differentiation 
    with glandular differentiation 
    with trophoblastic differentiation 
    Nested 
    Microcystic 
    Micropapillary  
    Lymphoepithelioma-like 3 
    Lymphoma-like 
    Plasmacytoid 
    Sarcomatoid  
    Giant cell  
    Undifferentiated  
Non-invasive urothelial neoplasias 
    Urothelial carcinoma in situ  
    Non-invasive papillary urothelial                    
carcinoma, high grade  
    Non-invasive papillary urothelial 
carcinoma, low grade  
    Non-invasive papillary urothelial neoplasm 
of low malignant potential  
    Urothelial papilloma  
    Inverted urothelial papilloma  
SQUAMOUS NEOPLASMS 
Squamous cell carcinoma  
Verrucous carcinoma  
Squamous cell papilloma  
GLANDULAR NEOPLASMS 
Adenocarcinoma  
    Enteric 
    Mucinous  
    Signet-ring cell  
    Clear cell    
Villous adenoma  
NEUROENDOCRINE TUMOURS 
Small cell carcinoma  
Carcinoid  
Paraganglioma  
MELANOCYTIC TUMOURS 
Malignant melanoma  
Nevus 
MESENCHYMAL TUMOURS 
Rhabdomyosarcoma  
Leiomyosarcoma  
Angiosarcoma  
Osteosarcoma  
Malignant fibrous histiocytoma  
Leiomyoma  
Haemangioma  
Others 
HAEMATOPOIETIC AND LYMPHOID 
TUMOURS 
Lymphoma 
Plasmacytoma  
MISCELLANEOUS TUMOURS 
Carcinoma of Skene, Cowper and Littre glands 
Metastatic tumours and tumours extending 
from other organs 
ANNEXURE II 
TNM STAGING OF BLADDER CARCINOMAS 
T– Primary tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Ta Non-invasive papillary carcinoma 
Tis Carcinoma in situ: "flat tumour" 
T1 Tumour invades subepithelial connective tissue 
T2 Tumour invades muscle 
     T2a Tumour invades superficial muscle (inner half) 
     T2b Tumour invades deep muscle (outer half) 
T3 Tumour invades perivesical tissue: 
     T3a Microscopically 
     T3b Macroscopically (extravesical mass) 
T4 Tumour invades any of the following: prostate, uterus, vagina, pelvic wall or abdominal 
wall 
     T4a Tumour invades prostate, uterus or vagina 
     T4b Tumour invades pelvic wall or abdominal wall 
N – Regional lymph nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single lymph node 2 cm or less in greatest dimension 
N2 Metastasis in a single lymph node more than 2 cm but not more than 5 cm in greatest 
dimension, or multiple lymph nodes, none more than 5 cm in greatest dimension 
N3 Metastasis in a lymph node more than 5 cm in greatest dimension 
M – Distant metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
STAGE GROUPING 
 
 
Stage 0a           Ta              N0                M0 
 
Stage 0             Tis             N0                M0 
 
Stage I              T1              N0                M0 
 
Stage II             T2a, b        N0                M0 
 
Stage III            T3a, b        N0                M0 
 
                          T4a            N0                M0 
 
Stage IV            T4b            N0                M0 
 
                          Any T        N1, N2, N3   M0 
 
                          Any T        Any N           M1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE III 
 
IMMUNOHISTOCHEMISTRY PROCEDURE 
 
1. 4µ thick sections were cut from formalin fixed paraffin embedded tissue 
samples and transferred to gelatin-chrome alum coated slides. 
2. The slides were incubated at 58ºC for overnight. 
3. The sections were deparaffinized in xylene for 15 minutes x 2 changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes x 2 
changes. 
5. The sections were washed in tap water for 10 minutes. 
6. The slides were then immersed in distilled water for 5 minutes. 
7. Heat induced antigen retrieval was done with microwave oven in 
appropriate temperature with appropriate buffer for 20 to 25 minutes. 
8. The slides were then cooled to room temperature and washed in running 
tap water for 5 minutes. 
9. The slides were then rinsed in distilled water for 5 minutes. 
10. Wash with appropriate wash buffer (citrate buffer) for 5 minutes x 2 
changes. 
11. Apply peroxidase block over the sections for 10 minutes. 
12. Wash the slides in citrate buffer for 5 minutes x 2 changes.  
13. Cover the sections with power block for 15 minutes. 
14. The sections were drained (without washing) and appropriate primary 
antibody was applied over the sections and incubated for 45 minutes. 
15. The slides were washed in citrate buffer for 5 minutes x 2 changes. 
16. The slides were covered with SuperEnhancer for 30 minutes. 
17. The slides were washed in citrate buffer for 5 minutes x 2 changes. 
18. The slides were covered with SS Label for 30 minutes. 
19. Wash in citrate buffer for 5 minutes x 2 changes. 
20. DAB substrate was prepared by diluting 1 drop of DAB chromogen to 1 
ml of DAB buffer. 
21. DAB substrate solution was applied on the sections for 8 minutes. 
22. Wash with citrate buffer solution for 5 minutes x 2 changes. 
23. The slides are washed well in running tap water for 5 minutes. 
24. The sections were counterstained with Hematoxylin stain for 2 seconds 
(1 dip). 
25. The slides are washed in running tap water for 3 minutes. 
26. The slides are air dried, cleared with xylene and mounted with DPX. 
 
ABSTRACT 
AIM:  
The variable prognosis of bladder cancer within a pathological stage 
necessitates the identification of subgroups of patients with a more aggressive disease. 
The role of microvessel density and HER-2/neu expression in transitional cell 
carcinomas of bladder is far from being fully established. The aim of the present study 
was to identify the incidence and distribution of bladder carcinoma in patients 
admitted in the Rajiv Gandhi Government General Hospital, Chennai in the year 2010 
and 2011 and to evaluate the role of microvessel density and HER-2/neu expression in 
transitional cell carcinomas of bladder and correlate the findings with several clinico-
pathological features and prognosis. 
MATERIALS AND METHODS:  
Formalin-fixed paraffin-embedded tissue samples from 50 patients of 
transitional cell carcinoma of bladder in the year 2010 to 2011 were studied by 
immunohistochemistry, using monoclonal antibodies to CD 34 and HER-2/neu. 
Microvessel density was found from CD 34 expression. The results were correlated 
with clinico-pathological features and prognostic factors. 
RESULTS: 
Microvessel density was significantly related with male gender, non-papillary 
tumours and with necrosis. Higher HER-2/neu expression correlated significantly with 
grade and urine cytology positivity.Increasing HER-2/neu expression correlated with 
age, male gender, multiple tumours, tumours with increased size, stage, infiltration, 
necrosis, sarcomatoid component, necrosis and with recurrence. Increasing 
microvessel density was associated with multiple tumours, higher grade, tumours with 
sarcomatoid component, positive urine cytology and in recurrence. Though 
microvessel density seemed to be decreasing with stage, the patients with high 
microvessel density (>50 vessels/200X) showed an increased rate of recurrence. 
CONCLUSION:  
 This study showed that increasing values of microvessel density and HER-
2/neu expression were found in patients with increasing stage, grade and recurrence. 
Thus they can be good prognostic factors for assessing patients presenting with early 
stage for the first time. A larger sample size will help in identifying the association 
between the stage, recurrence, microvessel density status and HER-2/neu expression. 
  
 
 
 
